var title_f24_43_25264="Pain scale children PI";
var content_f24_43_25264=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F51303&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F51303&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 499px\">",
"   <div class=\"ttl\">",
"    Wong-Baker FACES pain rating scale",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 479px; height: 163px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Explain to the child that each face is for a person who feels happy because he has no pain (hurt) or sad because he has some or a lot of pain. Face 0 is very happy because he doesn't hurt at all. Face 1 hurts just a little bit. Face 2 hurts a little more. Face 3 hurts even more. Face 4 hurts a whole lot. Face 5 hurts as much as you can imagine, although you don't have to be crying to feel this bad. Ask the child to choose the face that best describes how he is feeling. Rating scale is recommended for persons age three years and older. Point to each face using the words to describe the pain intensity. Ask the child to choose the face that best describes own pain and record the appropriate number.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wong DL, Hockenberry-Eaton M, Wilson D, et al. Wong's Essentials of Pediatric Nursing, 6th ed. Mosby, St. Louis, 2001. p.301. Copyright &copy; 2001 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_43_25264=[""].join("\n");
var outline_f24_43_25264=null;
var title_f24_43_25265="Scapular row exercise";
var content_f24_43_25265=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F86035&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F86035&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 537px\">",
"   <div class=\"ttl\">",
"    Scapular row exercise",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 517px; height: 199px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Start by holding tubing with some tension with the&nbsp;arms fully extended. Pull your shoulder blades back together; imagine you are pinching a pencil between your shoulder blades. As you pull back, allow your elbows to bend as if they were sliding along a table top. Complete the pull on a 2 count, and then slowly return to starting position on a 4 count. Perform 25 repetitions to complete one set, rest 30 seconds, and repeat for 2 sets of 25 repetitions. Be sure to pull with your shoulder blades; your arms should follow the shoulder blade movement.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Craig Parsons, MS, PT and the Physical Therapy Network.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_43_25265=[""].join("\n");
var outline_f24_43_25265=null;
var title_f24_43_25266="Patient information: Skin burns (The Basics)";
var content_f24_43_25266=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15740\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/8/27790\">",
"         Superficial burn",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/18/19744\">",
"          Superficial partial-thickness burn",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/24/16768\">",
"           Deep partial-thickness burn",
"          </a>",
"          <li>",
"           <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/12/2240\">",
"            Full-thickness burn",
"           </a>",
"          </li>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?32/51/33586\">",
"         Patient information: Electrical burns (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?31/55/32625\">",
"         Patient information: Skin burns (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Skin burns (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/skin-burns-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H30482216\">",
"      <span class=\"h1\">",
"       What are the symptoms of a skin burn?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms depend on how bad your skin burn is. Here are the terms doctors use to describe different types of burns:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Superficial skin burn",
"        </strong>",
"        (used to be called a &ldquo;first-degree burn&rdquo;): The burn is only on the top layer of your skin. Your skin will be dry, red, and painful (",
"        <a class=\"graphic graphic_picture graphicRef60417 \" href=\"UTD.htm?27/8/27790\">",
"         picture 1",
"        </a>",
"        ). When you press the burn, it turns white. Superficial skin burns heal in 3 to 6 days without leaving a scar.",
"       </li>",
"       <li>",
"        <strong>",
"         Superficial partial-thickness burn",
"        </strong>",
"        (used to be called a &ldquo;second-degree burn&rdquo;): The burn is on the top 2 layers of your skin, but does not go deep into the second layer. Your skin will hurt with a light touch or if the air temperature changes. The skin will be red and leak fluid, and you might get blisters (",
"        <a class=\"graphic graphic_picture graphicRef65552 \" href=\"UTD.htm?19/18/19744\">",
"         picture 2",
"        </a>",
"        ). The burn will turn white when you press it. Superficial partial-thickness burns take 7 to 21 days to heal, and the area of skin that was burned might be darker or lighter than it used to be. The burn might or might not leave a scar.",
"       </li>",
"       <li>",
"        <strong>",
"         Deep partial-thickness burn",
"        </strong>",
"        (used to be called a &ldquo;third-degree burn&rdquo;): This kind of burn also affects the top 2 layers of skin, but is deeper than a superficial partial-thickness burn (",
"        <a class=\"graphic graphic_picture graphicRef54524 \" href=\"UTD.htm?16/24/16768\">",
"         picture 3",
"        </a>",
"        ). The burn will hurt when you press it hard, but it will not turn white. You will get blisters. This kind of burn takes more than 21 days to heal, and will probably leave a scar.",
"       </li>",
"       <li>",
"        <strong>",
"         Full-thickness burn",
"        </strong>",
"        (used to be called a &ldquo;fourth-degree burn&rdquo;): Full-thickness burns include all the layers of the skin and often affect the fat and muscle underneath. The burn does not usually hurt, and the burned skin can be white, gray, or black (",
"        <a class=\"graphic graphic_picture graphicRef63587 \" href=\"UTD.htm?2/12/2240\">",
"         picture 4",
"        </a>",
"        ). The skin feels dry. Your doctor will treat this kind of burn with surgery. You might also need to stay in the hospital for a time and take medicines.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H30482223\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See your doctor or nurse right away if you are not sure how bad your burn is, or if the burn:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Involves your face, hands, feet, or genitals",
"       </li>",
"       <li>",
"        Is on or near a joint, such as your knee or shoulder",
"       </li>",
"       <li>",
"        Goes all the way around a part of your body (such as your arm or leg)",
"       </li>",
"       <li>",
"        Is bigger than 3 inches across or goes deep into the skin",
"       </li>",
"       <li>",
"        Causes a fever of at least 100.4&deg;F or shows other signs of infection. Infected skin gets more and more red, is painful, and may leak pus.",
"       </li>",
"       <li>",
"        Goes deeper than the top layer of skin AND you have not had a tetanus shot in more than 5 years",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People younger than 5 years or older than 70 years with any kind of skin burn should also see their doctor. Plus, people who have trouble fighting infection, for example because they have cancer or HIV, should see a doctor if they have a burn that goes deeper than a superficial burn.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H30482230\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your burn is not too severe, you can take the following steps:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Clean the burn: Take any clothes off of the area and wash it with cool water and plain soap. If your clothes stick to the burn, go to the emergency room.",
"       </li>",
"       <li>",
"        Cool the burn: After you have cleaned the skin, you can put a cool cloth on it or soak your skin in cool water. Do not use ice to cool the burn.",
"       </li>",
"       <li>",
"        Prevent infection: If the burn goes deeper than the top layer of skin, you are at risk of infection. To help prevent infection, you can use aloe vera gel or cream, or an antibiotic cream. If your burn forms blisters, cover it with a clean, non-stick bandage and change the bandage once or twice a day. Do not pop the blisters, because that can lead to infection.",
"       </li>",
"       <li>",
"        Treat pain: If the burn hurts, try raising the burned part of your body to a level above your heart. For instance, if you burned your foot, try lying down and propping your foot up on pillows. This slows blood flow to the area and can prevent swelling and ease pain. You can also take over-the-counter pain medicine, such as",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20021?source=see_link\">",
"         acetaminophen",
"        </a>",
"        (sold as Tylenol&reg;) or",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        (sold as Advil&reg; or Motrin&reg;).",
"       </li>",
"       <li>",
"        Do not scratch the burn: Scratching can increase the risk of infection.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H30482237\">",
"      <span class=\"h1\">",
"       How is a skin burn treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If the burn does not need a doctor&rsquo;s care right away, the first step is to try the things you can do on your own. If you have a more serious burn, your doctor might give you a stronger medicine for pain or apply special bandages. For a severe burn, your doctor might suggest surgery to repair the area that was burned. He or she might also prescribe medicines to prevent infection.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H30482244\">",
"      <span class=\"h1\">",
"       Can skin burns be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can reduce the chances that you or your children will get burned by:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Keeping candles, matches, and lighters away from children",
"       </li>",
"       <li>",
"        Keeping any hot objects away from the edge of the table or stove (examples include foods or liquids, or the handles of pots and pans)",
"       </li>",
"       <li>",
"        Using a humidifier with cool mist, not warm mist or steam",
"       </li>",
"       <li>",
"        Keeping children away from hot stoves, fireplaces, and ovens",
"       </li>",
"       <li>",
"        Having a smoke detector on each floor of your home",
"       </li>",
"       <li>",
"        Dressing your children in clothes that do not catch fire easily&mdash;especially at night. Clothes made from cotton are a good choice.",
"       </li>",
"       <li>",
"        Setting your hot-water heater no higher than 120&deg;F",
"       </li>",
"       <li>",
"        Covering car seats and seat belts with a cloth if the car is sitting in the sun on a hot day",
"       </li>",
"       <li>",
"        Using sunscreen if you are going to be in the sun",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H30482286\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/55/32625?source=see_link\">",
"       Patient information: Skin burns (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/51/33586?source=see_link\">",
"       Patient information: Electrical burns (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?24/43/25266?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15740 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-F93BED5DA7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_43_25266=[""].join("\n");
var outline_f24_43_25266=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30482216\">",
"      What are the symptoms of a skin burn?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30482223\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30482230\">",
"      Is there anything I can do on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30482237\">",
"      How is a skin burn treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30482244\">",
"      Can skin burns be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30482286\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15740\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/8/27790\">",
"      Superficial burn",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/18/19744\">",
"       Superficial partial-thickness burn",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/24/16768\">",
"        Deep partial-thickness burn",
"       </a>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/12/2240\">",
"         Full-thickness burn",
"        </a>",
"       </li>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/51/33586?source=related_link\">",
"      Patient information: Electrical burns (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/55/32625?source=related_link\">",
"      Patient information: Skin burns (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_43_25267="Nail anatomy";
var content_f24_43_25267=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F76994&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F76994&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal nail anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 426px; height: 273px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The nail has several distinct anatomic areas. The hard nail plate emerges from a matrix of specialized epithelial cells. The matrix begins 7 to 8 mm under the proximal fold, and its distal end is the white crescent called the lunula. The richly vascularized nail bed lies directly beneath the plate to provide adherence and support and is the basis of the characteristic pink color. The proximal and lateral nail folds surround the plate on three sides, and the cuticle, an outgrowth of the proximal fold, provides a seal between the fold and the nail plate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fitzpatrick, TB, Johnson, AB, Wolff, K, Suurmond, D. Color Atlas and Synopsis of Clinical Dermatology: Common and Serious Diseases, 4th edition. McGraw-Hill, New York 2001. Copyright &copy; 2001 The McGraw-Hill Companies.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_43_25267=[""].join("\n");
var outline_f24_43_25267=null;
var title_f24_43_25268="Guaifenesin and codeine: Patient drug information";
var content_f24_43_25268=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Guaifenesin and codeine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/15/44277?source=see_link\">",
"     see \"Guaifenesin and codeine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/26/34213?source=see_link\">",
"     see \"Guaifenesin and codeine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F177668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Allfen CD;",
"     </li>",
"     <li>",
"      Allfen CDX;",
"     </li>",
"     <li>",
"      Codar&reg; GF;",
"     </li>",
"     <li>",
"      Dex-Tuss;",
"     </li>",
"     <li>",
"      Guaiatussin AC;",
"     </li>",
"     <li>",
"      Iophen C-NR;",
"     </li>",
"     <li>",
"      M-Clear;",
"     </li>",
"     <li>",
"      M-Clear WC;",
"     </li>",
"     <li>",
"      Mar-Cof&reg; CG;",
"     </li>",
"     <li>",
"      Robafen AC",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691653",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to thin mucous so it can be taken from the body by coughing.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702220",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to guaifenesin, codeine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703713",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have asthma.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697679",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is not for coughs due to smoking or lung disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697135",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a history of a drug or drinking problem, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have PKU, talk with your doctor. Some products have phenylalanine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (solution, syrup) if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10012189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10012194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12521 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-6720EAAD2F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_43_25268=[""].join("\n");
var outline_f24_43_25268=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177668\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012186\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012185\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012190\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012191\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012193\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012188\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012189\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012194\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012195\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?43/15/44277?source=related_link\">",
"      Guaifenesin and codeine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/26/34213?source=related_link\">",
"      Guaifenesin and codeine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_43_25269="HGE in neutrophil EM";
var content_f24_43_25269=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F50113&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F50113&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Human granulocytic ehrlichiosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 304px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electron micrograph showing the human granulocytic ehrlichiosis agent in intracytoplasmic vacuoles (morulae) in a neutrophil.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Vsevolod Popov, PhD and Stephen Dumler, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_43_25269=[""].join("\n");
var outline_f24_43_25269=null;
var title_f24_43_25270="DLBCL centroblast variant";
var content_f24_43_25270=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F82926&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F82926&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Centroblast variant of diffuse large B-cell lymphoma in a lymph node biopsy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 318px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tumor cells show large round or oval nuclei with multiple membrane-bound nucleoli (arrow) and scanty cytoplasm. Hematoxylin and eosin, 100x magnification.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sun T. Clinical application, case 32 diffuse large B-cell lymphoma. In: Flow Cytometry, Immunohistochemistry, and Molecular Genetics for Hematologic Neoplasms, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_43_25270=[""].join("\n");
var outline_f24_43_25270=null;
var title_f24_43_25271="Neurogenic pulmonary edema";
var content_f24_43_25271=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Neurogenic pulmonary edema",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/43/25271/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/43/25271/contributors\">",
"     Jess Mandel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/43/25271/contributors\">",
"     Frank W Drislane, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/43/25271/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/43/25271/contributors\">",
"     Polly E Parsons, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/43/25271/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/43/25271/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/43/25271/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurogenic pulmonary edema (NPE) is an increase in pulmonary interstitial and alveolar fluid that is due to an acute central nervous system injury and usually develops rapidly after the injury [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25271/abstract/1\">",
"     1",
"    </a>",
"    ]. It is sometimes classified as a form of the acute respiratory distress syndrome (ARDS), but its pathophysiology and prognosis are different.",
"   </p>",
"   <p>",
"    The clinical features, differential diagnosis, diagnosis, etiology, pathogenesis, and treatment of NPE are reviewed here. ARDS and noncardiogenic pulmonary edema due to other causes are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=see_link\">",
"     \"Acute respiratory distress syndrome: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/57/1944?source=see_link\">",
"     \"Noncardiogenic pulmonary edema\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;NPE characteristically presents within minutes to hours of a severe central nervous system insult. However, more rapid onset (immediate) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25271/abstract/2\">",
"     2",
"    </a>",
"    ] and delayed onset (hours to days) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25271/abstract/3,4\">",
"     3,4",
"    </a>",
"    ] have been described. Resolution usually occurs within several days [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25271/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dyspnea is the most common symptom, although mild hemoptysis is present in many patients. The physical examination generally reveals tachypnea, tachycardia, and basilar rales. Chest radiographs typically show a normal size heart with bilateral alveolar filling, although findings that mimic heart failure (eg, cephalization of blood flow) may also occur [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25271/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Hemodynamic measurements are usually normal by the time NPE is diagnosed, including the blood pressure, cardiac output, and pulmonary capillary wedge pressure.",
"   </p>",
"   <p>",
"    There is a broad range of severities of NPE and mild cases may never be detected. While NPE can be fulminant and contribute to death, mortality is more commonly due to the neurologic disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical findings of NPE may be confused with aspiration pneumonitis. Reliable differentiation between these syndromes is difficult because they are both common in settings of altered consciousness, such as postictal states. NPE tends to develop more rapidly than aspiration pneumonia, while fever and focal infiltrates favor aspiration. In addition, NPE tends to resolve more rapidly than aspiration, particularly if aspiration pneumonia develops.",
"   </p>",
"   <p>",
"    Other causes of pulmonary edema should also be considered, such as heart failure and acute respiratory distress syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=see_link\">",
"     \"Evaluation of the patient with suspected heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=see_link\">",
"     \"Acute respiratory distress syndrome: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitive diagnosis of NPE is difficult because the clinical signs and routine diagnostic tests are nonspecific. Thus, NPE is a clinical diagnosis based upon the occurrence of pulmonary edema in the appropriate setting and in the absence of a more likely alternative cause.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary precipitants of NPE are epileptic seizures, head injuries, and cerebral hemorrhages [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25271/abstract/3,8\">",
"     3,8",
"    </a>",
"    ]. Less common etiologies are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef57483 \" href=\"UTD.htm?29/45/30427\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25271/abstract/9-12\">",
"     9-12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Epileptic seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epileptic seizures are the most common cause of NPE [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25271/abstract/3,8\">",
"     3,8",
"    </a>",
"    ]. Several case series reported that up to one-third of patients with fatal status epilepticus had clinical evidence of NPE [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25271/abstract/8,13\">",
"     8,13",
"    </a>",
"    ], while an autopsy study found that 87 percent of patients with epilepsy and unexplained sudden death had NPE [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25271/abstract/14\">",
"     14",
"    </a>",
"    ]. It is uncertain whether NPE was the proximate cause of death in these studies [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25271/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    NPE due to epileptic seizures generally occurs during the postictal period and it may occur repeatedly in a given individual [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25271/abstract/3,16,17\">",
"     3,16,17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19642?source=see_link\">",
"     \"Status epilepticus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Head injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blunt or penetrating head injury and neurosurgical procedures can cause NPE [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25271/abstract/2,3,18\">",
"     2,3,18",
"    </a>",
"    ]. The NPE is usually associated with elevated intracranial pressure (ICP), but raised ICP is not a necessary condition [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25271/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33402?source=see_link\">",
"     \"Evaluation and management of elevated intracranial pressure in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cerebral hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;NPE can complicate subarachnoid hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25271/abstract/4,7,20,21\">",
"     4,7,20,21",
"    </a>",
"    ]. In a series of 78 cases of fatal subarachnoid hemorrhage, 31 percent had antemortem clinical evidence of NPE and 71 percent had pathological evidence of NPE at autopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25271/abstract/20\">",
"     20",
"    </a>",
"    ]. NPE infrequently develops several days after the hemorrhage or recurs after apparent resolution [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25271/abstract/22\">",
"     22",
"    </a>",
"    ]. The most important risk factors for NPE following subarachnoid hemorrhage are the clinical and radiographic severities of the bleed and having a vertebral artery as the source of the bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25271/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    NPE can also follow intracerebral hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25271/abstract/4,7\">",
"     4,7",
"    </a>",
"    ]. However, the frequency and risk factors have not been well characterized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The neurological structures that are critical to the development of NPE are known. However, the mechanism by which lesions in these structures produce NPE is not well understood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Neurologic structures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The medulla oblongata is considered the critical anatomic structure involved in the pathogenesis of NPE. Its importance is supported by the observation that bilateral lesions in the nucleus of the solitary tract and lesions in the A1 neuroadrenergic neurons (both of which are in the medulla) can cause systemic hypertension and NPE [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25271/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The medulla oblongata probably acts via the sympathetic component of the autonomic nervous system, as suggested by the following evidence from animal models [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25271/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Alpha adrenergic blockade (eg, with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/43/34485?source=see_link\">",
"       phentolamine",
"      </a>",
"      ) can prevent the development of NPE.",
"     </li>",
"     <li>",
"      NPE can be prevented by spinal cord transection at or above the C7 level, below which sympathetic fibers leave the lateral part of the cord to form the paraspinal sympathetic trunks.",
"     </li>",
"     <li>",
"      NPE can be prevented by denervation by transection of the splanchnic sympathetic fibers to the lungs.",
"     </li>",
"     <li>",
"      NPE may be produced by stimulation of the cord at the C7-C8 level, with the cord and sympathetic nerves intact.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to the role of the medulla oblongata, theories regarding the pathogenesis of NPE have centered on the potential contributions of the hypothalamus, elevated intracranial pressure, and activation of the sympathoadrenal system [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25271/abstract/23-37\">",
"     23-37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Mechanisms of edema formation",
"    </span>",
"    &nbsp;&mdash;&nbsp;NPE requires a central nervous system injury or event (eg, seizure) that alters the Starling's forces in a way that increases the movement of fluid from the capillaries to the pulmonary interstitium, increases the permeability of the pulmonary capillaries, or both (",
"    <a class=\"graphic graphic_figure graphicRef66819 \" href=\"UTD.htm?38/2/38957\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Capillary hydrostatic pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased capillary hydrostatic pressure is the Starling's force that is most likely to contribute to NPE, since it is unlikely that a central nervous system injury or event could change capillary or interstitial oncotic pressure rapidly [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25271/abstract/3\">",
"     3",
"    </a>",
"    ]. This is supported by the observation that alveolar fluid has a low fluid to serum protein ratio early during the course of NPE, consistent with hydrostatic pulmonary edema [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25271/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Experimental studies using animal models and uncontrolled observations in humans suggest several mechanisms by which pulmonary capillary hydrostatic pressure may increase acutely:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonary venoconstriction may occur with intracranial hypertension or sympathetic stimulation. This increases the pulmonary capillary hydrostatic pressure, producing pulmonary edema [",
"      <a class=\"abstract\" href=\"UTD.htm?24/43/25271/abstract/25,39-42\">",
"       25,39-42",
"      </a>",
"      ]. Alpha adrenergic antagonists may attenuate the effect [",
"      <a class=\"abstract\" href=\"UTD.htm?24/43/25271/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Left ventricular performance may deteriorate due to systemic hypertension, negative inotropic influences of excessive vagal tone, and excessive venous return to the heart. This can cause passive elevation of the left atrial and pulmonary capillary pressures, leading to pulmonary edema [",
"      <a class=\"abstract\" href=\"UTD.htm?24/43/25271/abstract/30,31,44-49\">",
"       30,31,44-49",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the evidence that increased pulmonary capillary hydrostatic pressure plays a role in NPE, there are likely additional contributors. This notion is based upon reports of NPE occurring with little or no elevation in the pulmonary capillary wedge pressure and in the absence of left atrial or systemic hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25271/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Pulmonary capillary permeability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased pulmonary capillary permeability may contribute to NPE. This idea is supported by the finding of protein-rich edema fluid in animal models and some patients with NPE, as well as the observation that NPE can occur in the absence of the hemodynamic alterations associated with pulmonary edema [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25271/abstract/4,38,50,51\">",
"     4,38,50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, a study used thermal green dye techniques to measure extravascular lung water in 18 patients with either head trauma or subarachnoid hemorrhage and 13 control patients (trauma patients without head injury) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25271/abstract/4\">",
"     4",
"    </a>",
"    ]. Nine of the 18 patients with brain injuries had pulmonary edema, defined as extravascular lung water values greater than two standard deviations above the control group mean. The pulmonary edema was independent of intracranial or pulmonary vascular pressure, suggesting increased vascular permeability.",
"   </p>",
"   <p>",
"    The mechanism by which neural influences produce changes in pulmonary vascular permeability have not been elucidated well. However, several hypotheses exist:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Epinephrine or norepinephrine may directly increase vascular permeability. Supporting this idea are the observations from animal models that alpha adrenergic blockade can protect against NPE and sympathetic stimulation can produce it [",
"      <a class=\"abstract\" href=\"UTD.htm?24/43/25271/abstract/43\">",
"       43",
"      </a>",
"      ]. However, the hypothesis is imperfect because direct infusion of these substances into the pulmonary circulation does not produce such an effect [",
"      <a class=\"abstract\" href=\"UTD.htm?24/43/25271/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Alpha adrenergic agonists released in response to brain injury may cause the release of a second mediator, which increases vascular permeability (eg, endorphins, histamine, bradykinin) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/43/25271/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An initial rapid increase in pulmonary vascular pressure (eg, due to pulmonary vasospasm",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      increased systemic venous return) may cause pulmonary microvascular injury with a subsequent increase in permeability [",
"      <a class=\"abstract\" href=\"UTD.htm?24/43/25271/abstract/53\">",
"       53",
"      </a>",
"      ]. This theory (ie, the \"blast theory\") is supported by studies in rabbits that found that pulmonary capillaries are damaged when pressures exceed 40 mmHg [",
"      <a class=\"abstract\" href=\"UTD.htm?24/43/25271/abstract/54\">",
"       54",
"      </a>",
"      ]. It is also supported by the observation that patients with NPE frequently have mild hemoptysis or pulmonary hemorrhage [",
"      <a class=\"abstract\" href=\"UTD.htm?24/43/25271/abstract/2\">",
"       2",
"      </a>",
"      ]. The hypothesis is imperfect because the rapid development of acute pulmonary hypertension is not a necessary condition for NPE [",
"      <a class=\"abstract\" href=\"UTD.htm?24/43/25271/abstract/55,56\">",
"       55,56",
"      </a>",
"      ] and in animal models elevated pulmonary vascular pressures do not invariably lead to NPE [",
"      <a class=\"abstract\" href=\"UTD.htm?24/43/25271/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Inflammatory mechanisms do not appear to play a role in the development of increased capillary permeability [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25271/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The outcome of patients with NPE is usually determined by the course of the neurologic insult and not the NPE. Thus, treatment should focus on the neurological disorder while NPE is managed in a supportive and conservative fashion. Many episodes of NPE are well tolerated and most resolve within 48 to 72 hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Supportive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with NPE are hypoxemic and require supplemental oxygen. The preferred method of administering the oxygen depends upon the severity of the hypoxemia. For patients with mild hypoxemia, administration via nasal cannula may be sufficient. More severe hypoxemia generally requires administration via a facemask or a nonrebreather mask. Oxygenation should be monitored continuously by pulse oximetry. A reasonable goal is to maintain the oxyhemoglobin saturation &ge;94 percent.",
"   </p>",
"   <p>",
"    Mechanical ventilation is necessary in some circumstances. It can be administered noninvasively (via a facemask) or invasively (via an endotracheal tube). Mechanical ventilation and the decision to intubate a patient are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13336?source=see_link\">",
"     \"Overview of mechanical ventilation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1850?source=see_link\">",
"     \"Noninvasive positive pressure ventilation in acute respiratory failure in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/12/22726?source=see_link\">",
"     \"The decision to intubate\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mechanical ventilation in patients with NPE is similar to that in patients with other causes of respiratory failure, although there are some important differences:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High levels of positive end expiratory pressure (PEEP) should be avoided because it can reduce cerebral venous return and worsen intracranial hypertension [",
"      <a class=\"abstract\" href=\"UTD.htm?24/43/25271/abstract/58,59\">",
"       58,59",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/60/30663?source=see_link&amp;anchor=H5#H5\">",
"       \"Positive end-expiratory pressure (PEEP)\", section on 'Intracranial disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Permissive hypercapnia should be avoided because it carries the risk of cerebral vasodilation and exacerbation of elevated intracranial pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?24/43/25271/abstract/1\">",
"       1",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27127?source=see_link&amp;anchor=H30730070#H30730070\">",
"       \"Permissive hypercapnia\", section on 'Contraindications'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prone ventilation has been used successfully in patients with NPE and severe hypoxemia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25271/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39078?source=see_link\">",
"     \"Prone ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Maintenance of low cardiac filling pressures with diuretics and limitation of intravenous fluids may decrease pulmonary edema. However, care must be taken to avoid compromise of cardiac output and cerebral perfusion. Pulmonary artery catheterization may be helpful in guiding therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25271/abstract/5\">",
"     5",
"    </a>",
"    ], but should be carefully chosen on a case-by-case basis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27128?source=see_link\">",
"     \"Pulmonary artery catheterization: Indications and complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of medications have been used to treat patients with NPE, but assessment of their effectiveness is difficult because of the small number of patients treated, the nonrandomized design of the studies, and the fact that NPE is usually a self-limited condition. Agents that have been evaluated include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beta adrenergic antagonists, which increase lymph flow and edema in sheep and reduce histamine-induced augmentation of pulmonary vascular permeability [",
"      <a class=\"abstract\" href=\"UTD.htm?24/43/25271/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"       Dobutamine",
"      </a>",
"      , which may increase cardiac output, decrease pulmonary capillary wedge pressure, and promote diuresis [",
"      <a class=\"abstract\" href=\"UTD.htm?24/43/25271/abstract/61,62\">",
"       61,62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"       Chlorpromazine",
"      </a>",
"      , which may act via blockade of alpha adrenergic receptors or by as yet undefined mechanisms [",
"      <a class=\"abstract\" href=\"UTD.htm?24/43/25271/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Alpha adrenergic blockers have been shown in animal models to prevent NPE or hasten its resolution [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25271/abstract/43\">",
"     43",
"    </a>",
"    ]. No human clinical trials have been performed. We believe that the efficacy and safety of alpha adrenergic blockers need to be established in humans with NPE before they are recommended for routine use. Until that time, alpha adrenergic blockers should only be used in situations where the goal is to lower the systemic blood pressure from dangerously high levels because precipitating systemic hypotension can diminish cerebral perfusion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17305?source=see_link\">",
"     \"Antihypertensive therapy to prevent recurrent stroke or transient ischemic attack\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33402?source=see_link\">",
"     \"Evaluation and management of elevated intracranial pressure in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neurogenic pulmonary edema (NPE) is an increase in pulmonary interstitial and alveolar fluid that is due to an acute central nervous system injury. It usually develops rapidly following the injury. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      NPE characteristically presents within minutes to hours of a severe central nervous system insult. Dyspnea is the most common symptom, although mild hemoptysis is present in many patients. The physical examination generally reveals tachypnea, tachycardia, and basilar rales. Chest radiographs typically show a normal size heart with bilateral alveolar filling, while hemodynamic measurements are usually normal. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      NPE is a clinical diagnosis based upon the occurrence of pulmonary edema in the appropriate setting and in the absence of a more likely alternative cause. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Differential diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The primary precipitants of NPE are epileptic seizures, head injuries, and cerebral hemorrhages. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The outcome of patients with NPE is usually determined by the course of the neurologic insult and not the NPE. Thus, treatment should focus on the neurological disorder and NPE should be managed in a supportive and conservative fashion. Many episodes of NPE are well tolerated and most resolve within 48 to 72 hours. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with NPE are hypoxemic and require supplemental oxygen. Some patients may require mechanical ventilation, which differs from that for other causes of respiratory failure in two ways: permissive hypercapnia and high levels of positive end expiratory pressure (PEEP) should be avoided. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Supportive care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A variety of medications have been used to treat patients with NPE, but their efficacy in this setting has not been established. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Medications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/1\">",
"      Baumann A, Audibert G, McDonnell J, Mertes PM. Neurogenic pulmonary edema. Acta Anaesthesiol Scand 2007; 51:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/2\">",
"      Simmons RL, Martin AM Jr, Heisterkamp CA 3rd, Ducker TB. Respiratory insufficiency in combat casualties. II. Pulmonary edema following head injury. Ann Surg 1969; 170:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/3\">",
"      Colice GL, Matthay MA, Bass E, Matthay RA. Neurogenic pulmonary edema. Am Rev Respir Dis 1984; 130:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/4\">",
"      Mackersie RC, Christensen JM, Pitts LH, Lewis FR. Pulmonary extravascular fluid accumulation following intracranial injury. J Trauma 1983; 23:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/5\">",
"      Lagerkranser M, Pehrsson K, Sylv&eacute;n C. Neurogenic pulmonary oedema. A review of the pathophysiology with clinical and therapeutic implications. Acta Med Scand 1982; 212:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/6\">",
"      Ell SR. Neurogenic pulmonary edema. A review of the literature and a perspective. Invest Radiol 1991; 26:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/7\">",
"      Fontes RB, Aguiar PH, Zanetti MV, et al. Acute neurogenic pulmonary edema: case reports and literature review. J Neurosurg Anesthesiol 2003; 15:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/8\">",
"      Simon RP. Neurogenic pulmonary edema. Neurol Clin 1993; 11:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/9\">",
"      Simon RP, Gean-Marton AD, Sander JE. Medullary lesion inducing pulmonary edema: a magnetic resonance imaging study. Ann Neurol 1991; 30:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/10\">",
"      Wright RS, Feuerman T, Brown J. Neurogenic pulmonary edema after trigeminal nerve blockade. Chest 1989; 96:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/11\">",
"      Lee DS, Kobrine A. Neurogenic pulmonary edema associated with ruptured spinal cord arteriovenous malformation. Neurosurgery 1983; 12:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/12\">",
"      Prager P, Nolan M, Andrews IP, Williams GD. Neurogenic pulmonary edema in enterovirus 71 encephalitis is not uniformly fatal but causes severe morbidity in survivors. Pediatr Crit Care Med 2003; 4:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/13\">",
"      Ohlmacher, AP. Acute pulmonary edema as a terminal event in certain forms of epilepsy. Am J Med Sci 1910; 139:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/14\">",
"      Leestma JE, Walczak T, Hughes JR, et al. A prospective study on sudden unexpected death in epilepsy. Ann Neurol 1989; 26:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/15\">",
"      Terrence CF, Rao GR, Perper JA. Neurogenic pulmonary edema in unexpected, unexplained death of epileptic patients. Ann Neurol 1981; 9:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/16\">",
"      Mulroy JJ, Mickell JJ, Tong TK, Pellock JM. Postictal pulmonary edema in children. Neurology 1985; 35:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/17\">",
"      Darnell JC, Jay SJ. Recurrent postictal pulmonary edema: a case report and review of the literature. Epilepsia 1982; 23:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/18\">",
"      Qin SQ, Sun W, Wang HB, Zhang QL. Neurogenic pulmonary edema in head injuries: analysis of 5 cases. Chin J Traumatol 2005; 8:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/19\">",
"      Popp AJ, Shah DM, Berman RA, et al. Delayed pulmonary dysfunction in head-injured patients. J Neurosurg 1982; 57:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/20\">",
"      Weir BK. Pulmonary edema following fatal aneurysm rupture. J Neurosurg 1978; 49:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/21\">",
"      Muroi C, Keller M, Pangalu A, et al. Neurogenic pulmonary edema in patients with subarachnoid hemorrhage. J Neurosurg Anesthesiol 2008; 20:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/22\">",
"      Fisher A, Aboul-Nasr HT. Delayed nonfatal pulmonary edema following subarachnoid hemorrhage. Case report. J Neurosurg 1979; 51:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/23\">",
"      Chen HI, Sun SC, Chai CY. Pulmonary edema and hemorrhage resulting from cerebral compression. Am J Physiol 1973; 224:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/24\">",
"      Chen HI, Chai CY. Integration of the cardiovagal mechanism in the medulla oblongata of the cat. Am J Physiol 1976; 231:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/25\">",
"      Maron MB, Dawson CA. Pulmonary venoconstriction caused by elevated cerebrospinal fluid pressure in the dog. J Appl Physiol 1980; 49:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/26\">",
"      Malik AB. Mechanisms of neurogenic pulmonary edema. Circ Res 1985; 57:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/27\">",
"      Hakim TS, van der Zee H, Malik AB. Effects of sympathetic nerve stimulation on lung fluid and protein exchange. J Appl Physiol 1979; 47:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/28\">",
"      GAMBLE JE, PATTON HD. Pulmonary edema and hemorrhage from preoptic lesions in rats. Am J Physiol 1953; 172:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/29\">",
"      REYNOLDS RW. PULMONARY EDEMA AS A CONSEQUENCE OF HYPOTHALAMIC LESIONS IN RATS. Science 1963; 141:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/30\">",
"      MAIRE FW, PATTON HD. Neural structures involved in the genesis of preoptic pulmonary edema, gastric erosions and behavior changes. Am J Physiol 1956; 184:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/31\">",
"      MAIRE FW, PATTON HD. Role of the splanchnic nerve and the adrenal medulla in the genesis of preoptic pulmonary edema. Am J Physiol 1956; 184:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/32\">",
"      Garcia-Uria J, Hoff JT, Miranda S, Nishimura M. Experimental neurogenic pulmonary edema Part 2: The role of cardiopulmonary pressure change. J Neurosurg 1981; 54:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/33\">",
"      Darragh TM, Simon RP. Nucleus tractus solitarius lesions elevate pulmonary arterial pressure and lymph flow. Ann Neurol 1985; 17:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/34\">",
"      Graf CJ, Rossi NP. Catecholamine response to intracranial hypertension. J Neurosurg 1978; 49:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/35\">",
"      Inobe JJ, Mori T, Ueyama H, et al. Neurogenic pulmonary edema induced by primary medullary hemorrhage: a case report. J Neurol Sci 2000; 172:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/36\">",
"      Keegan MT, Lanier WL. Pulmonary edema after resection of a fourth ventricle tumor: possible evidence for a medulla-mediated mechanism. Mayo Clin Proc 1999; 74:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/37\">",
"      Sed&yacute; J, Zicha J, Kunes J, et al. Mechanisms of neurogenic pulmonary edema development. Physiol Res 2008; 57:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/38\">",
"      Smith WS, Matthay MA. Evidence for a hydrostatic mechanism in human neurogenic pulmonary edema. Chest 1997; 111:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/39\">",
"      Hoff JT, Nishimura M, Garcia-Uria J, Miranda S. Experimental neurogenic pulmonary edema. Part 1: The role of systemic hypertension. J Neurosurg 1981; 54:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/40\">",
"      Kadowitz PJ, Joiner PD, Hyman AL. Influence of sympathetic stimulation and vasoactive substances on the canine pulmonary veins. J Clin Invest 1975; 56:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/41\">",
"      El-Bermani AW. Innervation of the microcirculation. Ann N Y Acad Sci 1982; 384:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/42\">",
"      Macmillan CS, Grant IS, Andrews PJ. Pulmonary and cardiac sequelae of subarachnoid haemorrhage: time for active management? Intensive Care Med 2002; 28:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/43\">",
"      Schraufnagel DE, Thakkar MB. Pulmonary venous sphincter constriction is attenuated by alpha-adrenergic antagonism. Am Rev Respir Dis 1993; 148:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/44\">",
"      Lloyd TC Jr. Effect of increased intracranial pressure on pulmonary vascular resistance. J Appl Physiol 1973; 35:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/45\">",
"      Brashear RE, Ross JC. Hemodynamic effects of elevated cerebrospinal fluid pressure: alterations with adrenergic blockade. J Clin Invest 1970; 49:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/46\">",
"      CAMPBELL GS, HADDY FJ. Circulatory changes and pulmonary lesions in dogs following increased intracranial pressure, and the effect of atropine upon such changes. Am J Physiol 1949; 158:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/47\">",
"      Wray NP, Nicotra MB. Pathogenesis of neurogenic pulmonary edema. Am Rev Respir Dis 1978; 118:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/48\">",
"      Mayer SA, Fink ME, Homma S, et al. Cardiac injury associated with neurogenic pulmonary edema following subarachnoid hemorrhage. Neurology 1994; 44:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/49\">",
"      Bahloul M, Chaari AN, Kallel H, et al. Neurogenic pulmonary edema due to traumatic brain injury: evidence of cardiac dysfunction. Am J Crit Care 2006; 15:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/50\">",
"      Kowalski ML, Didier A, Kaliner MA. Neurogenic inflammation in the airways. I. Neurogenic stimulation induces plasma protein extravasation into the rat airway lumen. Am Rev Respir Dis 1989; 140:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/51\">",
"      McClellan MD, Dauber IM, Weil JV. Elevated intracranial pressure increases pulmonary vascular permeability to protein. J Appl Physiol 1989; 67:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/52\">",
"      Rosell S. Neuronal control of microvessels. Annu Rev Physiol 1980; 42:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/53\">",
"      Theodore J, Robin ED. Speculations on neurogenic pulmonary edema (NPE). Am Rev Respir Dis 1976; 113:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/54\">",
"      West JB, Mathieu-Costello O. Stress failure of pulmonary capillaries: role in lung and heart disease. Lancet 1992; 340:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/55\">",
"      Bowers RE, McKeen CR, Park BE, Brigham KL. Increased pulmonary vascular permeability follows intracranial hypertension in sheep. Am Rev Respir Dis 1979; 119:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/56\">",
"      Touho H, Karasawa J, Shishido H, et al. Neurogenic pulmonary edema in the acute stage of hemorrhagic cerebrovascular disease. Neurosurgery 1989; 25:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/57\">",
"      Landolt CC, Matthay MA, Albertine KH, et al. Overperfusion, hypoxia, and increased pressure cause only hydrostatic pulmonary edema in anesthetized sheep. Circ Res 1983; 52:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/58\">",
"      Colice GL. Neurogenic pulmonary edema. Clin Chest Med 1985; 6:473.",
"     </a>",
"    </li>",
"    <li>",
"     Cohen NH. Ventilator management in the NICU. In: Critical Care, Kelly B (Ed), American Academy of Neurology Course, Annual Meeting, 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/60\">",
"      Fletcher SJ, Atkinson JD. Use of prone ventilation in neurogenic pulmonary oedema. Br J Anaesth 2003; 90:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/61\">",
"      Knudsen F, Jensen HP, Petersen PL. Neurogenic pulmonary edema: treatment with dobutamine. Neurosurgery 1991; 29:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/62\">",
"      Deehan SC, Grant IS. Haemodynamic changes in neurogenic pulmonary oedema: effect of dobutamine. Intensive Care Med 1996; 22:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25271/abstract/63\">",
"      Wohns RN, Tamas L, Pierce KR, Howe JF. Chlorpromazine treatment for neurogenic pulmonary edema. Crit Care Med 1985; 13:210.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1610 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-197.136.42.3-A295DD27D0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_43_25271=[""].join("\n");
var outline_f24_43_25271=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Epileptic seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Head injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cerebral hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Neurologic structures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Mechanisms of edema formation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Capillary hydrostatic pressure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Pulmonary capillary permeability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Supportive care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1610\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1610|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/2/38957\" title=\"figure 1\">",
"      Capillary hemodynamics I",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1610|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/45/30427\" title=\"table 1\">",
"      Causes of NPE",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=related_link\">",
"      Acute respiratory distress syndrome: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17305?source=related_link\">",
"      Antihypertensive therapy to prevent recurrent stroke or transient ischemic attack",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33402?source=related_link\">",
"      Evaluation and management of elevated intracranial pressure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=related_link\">",
"      Evaluation of the patient with suspected heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/57/1944?source=related_link\">",
"      Noncardiogenic pulmonary edema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1850?source=related_link\">",
"      Noninvasive positive pressure ventilation in acute respiratory failure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13336?source=related_link\">",
"      Overview of mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27127?source=related_link\">",
"      Permissive hypercapnia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/60/30663?source=related_link\">",
"      Positive end-expiratory pressure (PEEP)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39078?source=related_link\">",
"      Prone ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27128?source=related_link\">",
"      Pulmonary artery catheterization: Indications and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19642?source=related_link\">",
"      Status epilepticus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/12/22726?source=related_link\">",
"      The decision to intubate",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_43_25272="Partial colpocleisis";
var content_f24_43_25272=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F51734&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F51734&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Le Fort partial colpocleisis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 565px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A-C) In Le Fort colpocleisis, rectangles of vaginal mucosa are removed from the anterior and posterior vaginal walls.",
"    <br>",
"     (D, E) The denuded areas are then sutured together, leaving (F) channels on each side open.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced with permission from: Mattingly, RF, Thompson, JD. TeLinde's Operative Gynecology, Sixth Edition. Philadelphia: JB Lippincott Co, 1985:562. Copyright &copy; 1985 Lippincott Williams &amp; Wilkins.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_43_25272=[""].join("\n");
var outline_f24_43_25272=null;
var title_f24_43_25273="Perianal complications of Crohn's disease";
var content_f24_43_25273=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Perianal complications of Crohn's disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/43/25273/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/43/25273/contributors\">",
"     Alain Bitton, MD, FRCPC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/43/25273/contributors\">",
"     Paul Belliveau, MDCM, FACS, FICS, FRCSC, MPA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/43/25273/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/43/25273/contributors\">",
"     Paul Rutgeerts, MD, PhD, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/43/25273/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/43/25273/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/43/25273/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Crohn's disease is a chronic recurrent inflammatory bowel disorder that can affect any gastrointestinal site from the oral cavity to the anus. The major perianal complications include fissures, fistulas, abscesses, and stenosis, alone or in combination, which affect approximately 35 to 45 percent of patients during the course of the disease. Symptoms can vary from anal pain and purulent discharge to bleeding and incontinence, and can be associated with significant morbidity and impaired quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major perianal complications of Crohn's disease will be reviewed here. The role of imaging in diagnosing anal abscesses and fistulas and the medical management of Crohn's disease are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19305?source=see_link\">",
"     \"Overview of the medical management of mild to moderate Crohn's disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6329?source=see_link\">",
"     \"Overview of the medical management of severe or refractory Crohn's disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/25/39319?source=see_link\">",
"     \"The role of imaging tests in the evaluation of anal abscesses and fistulas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=see_link\">",
"     \"Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/31/7673?source=see_link\">",
"     \"Immunomodulator therapy in Crohn's disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The American Gastroenterological Association (AGA) guidelines for perianal Crohn's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/4\">",
"     4",
"    </a>",
"    ], as well as other AGA guidelines, can be accessed through the AGA web site at",
"    <a class=\"external\" href=\"file://www.gastro.org/practice/medical-position-statements\">",
"     www.gastro.org/practice/medical-position-statements",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Age, race, and disease location are factors associated with perianal complications in Crohn's disease. The role of gender is less certain.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gender &ndash; Conflicting data exist regarding the relationship between gender and the incidence of perianal disease in Crohn's disease [",
"      <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/5,6\">",
"       5,6",
"      </a>",
"      ]. One report found an increased incidence of fistulas among males [",
"      <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/6\">",
"       6",
"      </a>",
"      ], while others found no difference [",
"      <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Age &ndash; Patients with Crohn's disease who are less than 40 years of age are at greater risk for perianal disease [",
"      <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/7\">",
"       7",
"      </a>",
"      ]. Patients who develop perianal complications at an early age or who have a fistula as the first manifestation of perianal disease may be at increased risk for abdominoperineal resection (proctectomy) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/8-10\">",
"       8-10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Race &ndash; Non-Caucasians and Sephardic Jews (as opposed to Ashkenazi Jews) with Crohn's disease have a higher risk for perianal disease [",
"      <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/5,7\">",
"       5,7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Disease location &ndash; Involvement of the perianal region is more common in patients with colonic (particularly rectal) or ileocolonic disease compared to those with disease restricted to the small bowel [",
"      <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/1,3,11\">",
"       1,3,11",
"      </a>",
"      ]. In one study, patients with Crohn's colitis were more than three times as likely to develop perianal fistulas as those with ileitis [",
"      <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/5\">",
"       5",
"      </a>",
"      ]. Patients who have rectal involvement with Crohn's disease are at increased risk for surgical resection [",
"      <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/8-10\">",
"       8-10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2503026\">",
"    <span class=\"h1\">",
"     INITIAL PRESENTATION WITH PERIANAL DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perianal disease can precede symptomatic intestinal disease by years, although the frequency with which this occurs varies (5 to 19 percent) among series [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/2,3,12,13\">",
"     2,3,12,13",
"    </a>",
"    ]. When perianal disease is the initial presentation of Crohn&rsquo;s disease, it may be difficult to distinguish from the hemorrhoids, fissures, and fistulas seen in patients who do not have Crohn&rsquo;s disease. A diagnosis of underlying Crohn&rsquo;s disease should be considered:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients whose perianal disease does not resolve with routine management",
"     </li>",
"     <li>",
"      In patients with unusual presentations (eg, anal fissures that are not located in the midline, complex anal fistulas, or large, indurated hemorrhoids)",
"     </li>",
"     <li>",
"      In patients who, upon further questioning, report symptoms that might suggest Crohn&rsquo;s disease (eg, diarrhea, rashes, joint pains) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=see_link\">",
"       \"Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Perianal disease without intestinal symptoms that persists over time is infrequent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ANAL FISSURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;An anal fissure is an ulcer in the lining of the anal canal distal to the dentate line. Anal fissures develop in approximately 20 percent of patients with Crohn's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/14\">",
"     14",
"    </a>",
"    ]. In patients with idiopathic anal fissures (ie, fissures that are not associated with Crohn&rsquo;s disease), the fissures almost always occur in the midline. Similarly, in patients with Crohn&rsquo;s disease, fissures most commonly occur in the posterior midline. However, the fissures are eccentrically located in up to 20 percent of patients with Crohn&rsquo;s disease-related fissures [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Anal fissures in patients with Crohn's disease spontaneously heal in more than 80 percent of patients (",
"    <a class=\"graphic graphic_picture graphicRef51583 \" href=\"UTD.htm?34/14/35040\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/24/34181?source=see_link\">",
"     \"Anal fissure: Clinical manifestations, diagnosis, prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to inflammatory bowel disease, the differential diagnosis of anal fissures includes local trauma (passage of hard stool), immunodeficiency states, sexually transmitted diseases (eg, chlamydia, gonorrhea, syphilis), neoplasms, and certain drugs. The antianginal drug nicorandil, for example, has been implicated [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Features that suggest Crohn's disease rather than sporadic anal fissures include: location other than the posterior midline; the presence of multiple, recurrent, or nonhealing fissures; and fissures that are asymptomatic. In addition, hypertrophic, edematous, and tender skin tags may be present, which are often mistaken for external hemorrhoids, but are characteristic of Crohn's disease and may show granulomas if biopsied (",
"    <a class=\"graphic graphic_picture graphicRef75104 graphicRef78460 \" href=\"UTD.htm?18/19/18744\">",
"     picture 2A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinical manifestations and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anal fissures in Crohn's disease may be asymptomatic or present with bleeding, deep ulceration (",
"    <a class=\"graphic graphic_picture graphicRef80569 \" href=\"UTD.htm?22/16/22784\">",
"     picture 3",
"    </a>",
"    ), or anal pain, which may be worsened during evacuation. The clinical course of anal fissures is usually benign; however, nonhealing fissures or deeper ulcers may lead to fistula or perianal abscess formation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Symptomatic relief",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although healing of the fissures is the ultimate goal, initial treatment should be aimed at relieving symptoms. This includes measures to decrease fecal soilage by reducing diarrhea and local cleansing with sitz baths. The anoderm should be kept clean and dry, but without excessive wiping or use of astringent cleaners. Bathing following defecation is helpful. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/24/34181?source=see_link\">",
"     \"Anal fissure: Clinical manifestations, diagnosis, prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no controlled trials showing that oral antibiotics are effective in the treatment of perianal fissures associated with Crohn's disease. The clinical practice of using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    is based upon uncontrolled case series that have shown that oral antibiotics such as metronidazole may be beneficial in addition to local measures if symptoms do not improve within three to five days. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/34/20008?source=see_link\">",
"     \"Antibiotics for treatment of inflammatory bowel diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one series of 21 consecutive patients with chronic, unremitting perianal Crohn's disease, drainage, erythema, and induration were improved after therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    (20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in divided doses) in all patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/20\">",
"     20",
"    </a>",
"    ]. Complete healing was achieved in 10 of 18 (56 percent) patients who were maintained on therapy.",
"   </p>",
"   <p>",
"    Side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    included a metallic taste, peripheral neuropathy, dark urine, paresthesias, and mild gastrointestinal upset. As initial therapy, we suggest using metronidazole, 500 mg orally twice daily, since paresthesias may develop at higher doses [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Metronidazole should be discontinued in patients who develop neuropathy.",
"   </p>",
"   <p>",
"    Although controlled trials are lacking,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    alone or in addition to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    has been used in patients who have perianal complications in association with active intestinal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Topical nitroglycerin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    0.2 percent is beneficial for patients with spontaneous chronic anal fissures. Its efficacy in patients with anal fissures in Crohn's disease has not been evaluated. Other topical ointments such as calcium channel blockers in reduced concentrations (1 percent) have been used. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/24/34181?source=see_link\">",
"     \"Anal fissure: Clinical manifestations, diagnosis, prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fissures that are resistant to conservative treatment may occasionally require surgery. Although there is concern about injuring the sphincter mechanism and the possibility of poor wound healing, procedures such as lateral internal sphincterotomy have been successful [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/10\">",
"     10",
"    </a>",
"    ]. This involves careful dissection of only a small portion of the internal sphincter with division of fibers up to the dentate line. Internal sphincterotomy can also be used when chronic fissures led to stricture formation. Surgery should be avoided in the presence of proctitis as it predisposes to poor healing [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/1/15384?source=see_link&amp;anchor=H72479863#H72479863\">",
"     \"Anal fissure: Medical and surgical management\", section on 'Surgical therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PERIANAL FISTULA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anorectal fistulas develop in approximately 20 to 30 percent of patients with Crohn's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/2,11,25\">",
"     2,11,25",
"    </a>",
"    ]. Up to 45 percent of these patients develop the fistula before being diagnosed with Crohn's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fistulas are usually the consequence of penetration of an abscess into an adjacent organ or the skin. Thus, a fistula may initially present as an abscess that, upon spontaneous draining, evolves into a fistulous tract (",
"    <a class=\"graphic graphic_picture graphicRef75104 graphicRef78460 \" href=\"UTD.htm?18/19/18744\">",
"     picture 2A-B",
"    </a>",
"    ). In patients without Crohn's disease, anal fistulas typically arise from the anal crypts and glands, but this is not always the case in those with Crohn's disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=see_link\">",
"     \"Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Anatomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fistulous openings most commonly involve the perianal skin, but can also be in the groin, vulva, or scrotum. The fistulas can be classified based upon their anatomic extensions. Fistulas may be simple or they may have complicated anatomy, with one or more extensions and accessory tracts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/51/5946?source=see_link&amp;anchor=H22288745#H22288745\">",
"     \"Operative management of anorectal fistulas\", section on 'Simple fistulas'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/51/5946?source=see_link&amp;anchor=H22288751#H22288751\">",
"     \"Operative management of anorectal fistulas\", section on 'Complex fistulas'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Classification of the area involved with the fistula is helpful in planning surgical intervention. Fistulas can be classified as follows (",
"    <a class=\"graphic graphic_figure graphicRef67826 \" href=\"UTD.htm?35/32/36355\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intersphincteric fistulas travel along the intersphincteric plane to the perianal skin",
"     </li>",
"     <li>",
"      Transsphincteric fistulas encompass a portion of the internal and external sphincter, and terminate on the skin overlying the buttock",
"     </li>",
"     <li>",
"      Suprasphincteric fistulas encompass the entire sphincter apparatus",
"     </li>",
"     <li>",
"      Extrasphincteric fistulas extend from an internal opening in the bowel proximal to the anus, encompass the entire sphincter apparatus, and open onto the skin overlying the buttocks",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Clinical manifestations and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fistulas can present with persistent anal pain, painful defecation, and perianal openings with purulent discharge. On physical examination, fistulas appear as single or multiple perianal openings, which may spontaneously discharge purulent material (",
"    <a class=\"graphic graphic_picture graphicRef75104 graphicRef78460 \" href=\"UTD.htm?18/19/18744\">",
"     picture 2A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef65699 \" href=\"UTD.htm?23/62/24546\">",
"     picture 4",
"    </a>",
"    ). Fistulas involving the urinary bladder or vagina may be associated with pneumaturia or passage of stool or a foul-smelling discharge through the vagina.",
"   </p>",
"   <p>",
"    The gold standard for evaluation of the anatomy of fistulas has traditionally been probing under general anesthesia. Less invasive imaging methods, such as fistulography and standard",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    studies, magnetic resonance imaging (MRI), helical computed tomography, and ultrasound, are generally less accurate, but may have a role in patients with high tracts into perirectal or pelvic areas who are seen in centers experienced with these techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/27-31\">",
"     27-31",
"    </a>",
"    ]. The combination of different imaging modalities appears to be more accurate than any one modality alone [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/31\">",
"     31",
"    </a>",
"    ]. MRI may have an important role in the evaluation of the completeness of healing of fistulas and the risk of relapse under anti-TNF therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/25/39319?source=see_link\">",
"     \"The role of imaging tests in the evaluation of anal abscesses and fistulas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment should be determined according to the patient's symptoms and the anatomic complexity of the fistulas. Much of the information on the treatment of fistulas in Crohn's disease is based upon case series, with few controlled trials. As a general rule, treatment of the underlying Crohn's disease should proceed as in patients with Crohn's disease without fistulas. Antibiotics have been used in the treatment of perianal fistulas in Crohn's disease, although controlled studies are lacking. Immunomodulator therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    , 6-mercaptopurine, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    is also an option in patients with severe or refractory fistulas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19305?source=see_link\">",
"     \"Overview of the medical management of mild to moderate Crohn's disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/31/7673?source=see_link\">",
"     \"Immunomodulator therapy in Crohn's disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44105?source=see_link\">",
"     \"Infliximab in Crohn's disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to oral antibiotics and immunomodulator therapy, topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    has also been studied for the treatment of perianal Crohn's disease, including fistulas. In a randomized trial, 74 patients with active perianal disease were assigned to receive either metronidazole 10 percent ointment three times daily or placebo ointment [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/33\">",
"     33",
"    </a>",
"    ]. Patients who received the metronidazole reported significantly less perianal discharge and there was a trend toward a reduction in perianal pain. There were no differences between the groups with regard to reduction in the Perianal Crohn's Disease Activity Index (the primary endpoint), the patient's global impression of improvement, or quality of live scores. The ointment was generally well tolerated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Asymptomatic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perianal fistulas that are asymptomatic may not require treatment. Many of these patients will remain asymptomatic or spontaneously heal. In one report that included 21 patients with perianal fistulas, 33 percent remained asymptomatic despite continued presence of the fistula, and 38 percent had spontaneous healing during 10 years of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Patients with mild to moderate symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with mild to moderate symptoms, treatment with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    has been used as initial therapy, although controlled studies are scarce [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/20,21,34,35\">",
"     20,21,34,35",
"    </a>",
"    ]. In addition, ongoing rectal inflammation should be treated with systemic or topical agents. In a prospective study of 52 patients, metronidazole (1000 to 1500 mg daily) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    (50 to 1000 mg daily) were useful for inducing a response in 50 percent by eight weeks; however, patients who had received prior treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    were more likely to achieve a response than those without immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19305?source=see_link\">",
"     \"Overview of the medical management of mild to moderate Crohn's disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6329?source=see_link\">",
"     \"Overview of the medical management of severe or refractory Crohn's disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The toxicity of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    can be limited by using a dose of 250 mg PO three times daily. In patients who do not respond (ie, with cessation of drainage and closure of the fistula) after six weeks of therapy, the dose can be increased up to 1.5",
"    <span class=\"nowrap\">",
"     g/day.",
"    </span>",
"   </p>",
"   <p>",
"    Relapses are frequent in patients who discontinue",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    . As a result, we continue treatment for 6 to 12 months, followed by a gradual tapering to one dose per day for maintenance in responding patients.",
"   </p>",
"   <p>",
"    In patients who develop side effects or who are intolerant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    (500 mg twice daily) may be an alternative [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Patients with severe or refractory disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunomodulator therapy should be considered in patients with symptomatic perianal fistulas who do not respond to antibiotics and local therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/38-43\">",
"     38-43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/31/7673?source=see_link\">",
"     \"Immunomodulator therapy in Crohn's disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44105?source=see_link\">",
"     \"Infliximab in Crohn's disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29559?source=see_link\">",
"     \"Adalimumab for treatment of Crohn's disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Various immunomodulators have been evaluated in the treatment of refractory perianal disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The chimeric anti-tumor necrosis factor (TNF) alpha monoclonal antibody",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      was approved for use in fistulizing Crohn's disease based upon the results of two randomized controlled trials [",
"      <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/40,44\">",
"       40,44",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44105?source=see_link\">",
"       \"Infliximab in Crohn's disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The humanized anti-TNF agent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      was also shown to be effective in inducing and maintaining fistula healing up to 56 weeks in Crohn's disease [",
"      <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/45\">",
"       45",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29559?source=see_link\">",
"       \"Adalimumab for treatment of Crohn's disease in adults\"",
"      </a>",
"      .) This effect was sustained for an additional year in an open-label extension study.",
"     </li>",
"     <li>",
"      Oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      has been evaluated in case reports and in one controlled trial [",
"      <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/43,46\">",
"       43,46",
"      </a>",
"      ]. Tacrolimus has the advantage of being readily absorbed, even from diseased small intestinal mucosa, and appears to be useful for the treatment of refractory inflammatory bowel disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/31/7673?source=see_link\">",
"       \"Immunomodulator therapy in Crohn's disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      6-mercaptopurine",
"      <span class=\"nowrap\">",
"       (6-MP)/",
"       <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"        azathioprine",
"       </a>",
"      </span>",
"      (AZA) &ndash; AZA and 6-MP have been shown to be effective treatments for patients with fistulas in Crohn's disease. A meta-analysis of five randomized controlled trials revealed AZA or 6-MP treatment resulted in complete healing or decreased discharge (54 versus 21 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/47\">",
"       47",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/31/7673?source=see_link\">",
"       \"Immunomodulator therapy in Crohn's disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other therapies &ndash; Other immunomodulators, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      , intralesional",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      , and topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      , have been tried in uncontrolled studies but their efficacy for perianal fistula remains to be determined [",
"      <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/48-50\">",
"       48-50",
"      </a>",
"      ]. Oral spherical adsorptive carbon showed some benefit over placebo in a small randomized controlled trial [",
"      <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Fibrin glue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibrin glue has been used to treat refractory fistulas in patients both with and without Crohn's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/52\">",
"     52",
"    </a>",
"    ]. In a series of 14 patients with Crohn's disease, injection of fibrin glue into the fistula (under general anesthesia with endoscopic ultrasound guidance) was associated with clinical remission in one-half of patients after two years of follow-up. There were no serious side-effects. Other studies have shown lower success rates [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. In an open labeled controlled trial in patients with mild or quiescent Crohn's disease and fistulas, remission was observed in 38 percent of patients who received fibrin glue therapy compared to 16 percent in those who did not [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/54\">",
"     54",
"    </a>",
"    ]. The benefit seemed to be greater in patients with simple fistulas. Further studies will help determine its role. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26246?source=see_link\">",
"     \"Perianal abscess: Clinical manifestations, diagnosis, treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery for anal fistula disease should be considered in patients who have simple low intersphincteric fistulas or fistulas refractory to medical therapy and those who have severe or disabling symptoms. However, surgery should not be performed in patients with active proctitis as postoperative diarrhea can be irritating to the wound and may be associated with prolonged healing.",
"   </p>",
"   <p>",
"    Better outcomes have been achieved when surgical and medical therapies are used in conjunction [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. Although perianal disease activity does not always parallel activity in the intestine or at other extraintestinal sites, patients whose intestinal disease is quiescent may have better outcomes after surgical treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/58\">",
"     58",
"    </a>",
"    ]. The goals of surgery are to eradicate the fistula while preserving fecal continence or to reduce symptoms by making management easier for the patient such as by transforming a complex fistula into one closer to the anus which is controllable by a small pad.",
"   </p>",
"   <p>",
"    The surgical approach depends upon the type of fistula and its anatomical extent. For patients with intersphincteric or low transsphincteric fistulas on probing under anaesthesia (general or regional), fistulotomy is advised and may lead to healing in a significant number. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/51/5946?source=see_link&amp;anchor=H22288799#H22288799\">",
"     \"Operative management of anorectal fistulas\", section on 'Fistulotomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A non-cutting silastic seton (a drain that is threaded into the cutaneous orifice of a fistula, through the fistula tract, and into the rectum and anal canal) may be helpful in some patients with more complex fistulas [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. These setons need to be left in place for several weeks before removal in clinic. Cutting setons should not be used in patients with fistulas due to Crohn&rsquo;s disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/51/5946?source=see_link&amp;anchor=H22288841#H22288841\">",
"     \"Operative management of anorectal fistulas\", section on 'Fistulotomy and setons'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some patients will require fecal diversion, but the disease often recurs once the fecal stream is restored. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/51/5946?source=see_link&amp;anchor=H22288949#H22288949\">",
"     \"Operative management of anorectal fistulas\", section on 'Diversion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Proctectomy may be required in patients with severe rectal disease associated with complex fistulas who fail more conservative medical and surgical therapy. It is required in 10 to 20 percent of patients with perianal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/61\">",
"     61",
"    </a>",
"    ]. Proctectomy may be complicated by poor wound healing and sinus tract formation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical and surgical therapies are successful in closing fistulas or controlling symptoms in the majority of patients.",
"   </p>",
"   <p>",
"    Whether immunosuppressive therapy will substantially decrease the recurrence rate and need for surgical intervention remains to be determined. In one report of 192 patients (followed up to week 54) who were classified as responders and randomized to maintenance",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every eight weeks) or placebo, those receiving infliximab had significantly fewer hospitalization days (0.5 versus 2.5), surgeries and procedures (65 versus 126), inpatient surgeries and procedures (7 versus 41), and major surgeries (2 versus 11) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fistula recurrence is common. This was illustrated in a prospective series of 90 patients with Crohn's disease in whom perianal fistulas had healed using medical or surgical approaches [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/35\">",
"     35",
"    </a>",
"    ]. Fistulas reopened in 44 percent within 18 months of healing. On multivariate analysis, recurrence rates were decreased in patients who had undergone fecal diversion and in those without rectal disease. In a retrospective series of 224 patients seen between 1984 and 1999, 62 percent retained anorectal function, while the remaining patients eventually underwent proctectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/63\">",
"     63",
"    </a>",
"    ]. Those with rectal involvement had a significantly higher rate of proctectomy than patients with rectal sparing (78 versus 14 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26246?source=see_link\">",
"     \"Perianal abscess: Clinical manifestations, diagnosis, treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     ANORECTAL ABSCESSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anorectal abscesses develop in approximately one-half of patients with perianal Crohn's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/64\">",
"     64",
"    </a>",
"    ]. Abscesses are most often related to anal fistulas (particularly ischiorectal fistulas) (",
"    <a class=\"graphic graphic_picture graphicRef75104 \" href=\"UTD.htm?34/20/35136\">",
"     picture 2A",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Anal abscesses can involve different planes in the anorectum, which may have distinct presentations and require specific therapy. Patients with abscesses may present with severe, constant pain in the anal area or have more subtle presentations with persistent anal pain that is worsened by sitting or defecation. In more severe cases, patients may have constitutional symptoms including fever and malaise. Purulent rectal drainage may be noted if the abscess has begun to drain spontaneously. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26246?source=see_link\">",
"     \"Perianal abscess: Clinical manifestations, diagnosis, treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On physical examination, an area of fluctuation or a patch of erythematous, indurated skin overlying the perianal or ischiorectal space may be noted (",
"    <a class=\"graphic graphic_picture graphicRef75104 \" href=\"UTD.htm?34/20/35136\">",
"     picture 2A",
"    </a>",
"    ). However, in some patients, and with some types of abscesses, there are no findings on physical inspection and the abscess can only be felt via digital rectal examination or seen on CT scan. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/25/39319?source=see_link\">",
"     \"The role of imaging tests in the evaluation of anal abscesses and fistulas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The goal of therapy is to drain the abscess cavity without damaging the anal sphincter. Adequate drainage should be accomplished rapidly to prevent the development of sepsis. The surgical approach can include local incision and drainage, catheter drainage, or seton placement [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. Despite successful treatment, anal abscesses recur in up to 50 percent of patients within one to two years [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26246?source=see_link\">",
"     \"Perianal abscess: Clinical manifestations, diagnosis, treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     ANAL STENOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term inflammation associated with anorectal Crohn's disease may lead to fibrosis with the development of anal stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/66\">",
"     66",
"    </a>",
"    ]. Anal stenosis can be treated with gentle therapeutic dilation, which can be performed during surgical therapy of a fistula. Maintenance therapy with a rectal steroid suspension given weekly may be of benefit. Some patients require instruction on periodic home dilation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     HEMORRHOIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Crohn's disease may develop hemorrhoids coincidentally to their bowel disease. Hemorrhoids should be distinguished from hypertrophied skin tags that are associated with perianal Crohn's disease. The latter are often tender, and may be associated with anal canal ulceration (",
"    <a class=\"graphic graphic_picture graphicRef75104 \" href=\"UTD.htm?34/20/35136\">",
"     picture 2A",
"    </a>",
"    ). Treatment for hemorrhoids should be local and conservative. Hemorrhoidectomy should be",
"    <strong>",
"     avoided",
"    </strong>",
"    because of the possibility of poor wound-healing and of damaging the anal sphincter. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/61/6105?source=see_link\">",
"     \"Treatment of hemorrhoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     RISK OF ADENOCARCINOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of intestinal carcinoma may be higher in patients with Crohn's disease who have stricturing disease or longstanding perianal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/67\">",
"     67",
"    </a>",
"    ]. Carcinoma (squamous or adenocarcinoma) can rarely develop within the fistulous tract [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25273/abstract/67,68\">",
"     67,68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Carcinoma should be suspected in patients who have fistulas containing exuberant granulation tissue and induration. In such patients, examination under general anesthesia with biopsy and curettage can increase the yield of diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/56/10115?source=see_link\">",
"       \"Patient information: Crohn's disease in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/40/24196?source=see_link\">",
"       \"Patient information: Crohn's disease (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/31/44529?source=see_link\">",
"       \"Patient information: Anal fissure (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The major perianal complications of Crohn's disease include fissures, fistulas, abscesses, and stenosis, alone or in combination.",
"     </li>",
"     <li>",
"      Patients with perianal disease due to Crohn&rsquo;s disease should be managed by physicians with expertise in the treatment of these disorders. Patients with complex fistulas should be treated by colorectal surgeons and gastroenterologists with significant experience in these conditions.",
"     </li>",
"     <li>",
"      Risk factors, such as younger age (less than 40 years of age), race (non-Caucasians and Sephardic Jews) and colonic disease may play a role in the development of perianal complications in Crohn's disease. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An anal fissure is a tear in the lining of the anal canal distal to the dentate line and develops in approximately 20 percent of patients with Crohn's disease. Fissures may be asymptomatic or present with bleeding, deep ulceration or anal pain. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Anal fissures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of anal fissures should be aimed at relieving symptoms. For patients whose symptoms are not alleviated within three to five days, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Metronidazole is given 500 mg orally twice daily for 7 to 10 days. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Anal fissures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anorectal fistulas develop in approximately 20 to 30 percent of patients with Crohn's disease. Fistulas can be classified based upon their anatomic extensions. The fistulous openings most commonly involve the perianal skin, but can also be in the groin, vulva, or scrotum. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Perianal fistula'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of fistulas should be determined according to the patient's symptoms and the anatomic complexity of the fistulas. In patients with mild to moderate Crohn's disease, we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      (500 mg twice daily) as initial therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In patients who do not respond (ie, with cessation of drainage and closure of the fistula) after six weeks of therapy, the dose can be increased up to 1.5",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      500 mg twice daily can be added. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Perianal fistula'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with severe or refractory perianal Crohn's disease, we suggest treatment of fistulas with an anti-TNF alpha agent,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       Azathioprine",
"      </a>",
"      and 6-mercaptopurine are alternatives for patients who are unable or unwilling to start an anti-TNF agent but are less effective. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Perianal fistula'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44105?source=see_link\">",
"       \"Infliximab in Crohn's disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29559?source=see_link\">",
"       \"Adalimumab for treatment of Crohn's disease in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6329?source=see_link&amp;anchor=H11188279#H11188279\">",
"       \"Overview of the medical management of severe or refractory Crohn's disease in adults\", section on 'Anti-TNF therapies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anorectal abscesses develop in approximately one-half of patients with perianal Crohn's disease. Adequate drainage should be accomplished rapidly to prevent the development of sepsis. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Anorectal abscesses'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgery should be considered in patients who have simple low intersphincteric fistulas or fistulas refractory to medical therapy and those who have severe or disabling symptoms. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/1\">",
"      Rankin GB, Watts HD, Melnyk CS, Kelley ML Jr. National Cooperative Crohn's Disease Study: extraintestinal manifestations and perianal complications. Gastroenterology 1979; 77:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/2\">",
"      McKee RF, Keenan RA. Perianal Crohn's disease--is it all bad news? Dis Colon Rectum 1996; 39:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/3\">",
"      Platell C, Mackay J, Collopy B, et al. Anal pathology in patients with Crohn's disease. Aust N Z J Surg 1996; 66:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/4\">",
"      American Gastroenterological Association Clinical Practice Committee. American Gastroenterological Association medical position statement: perianal Crohn's disease. Gastroenterology 2003; 125:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/5\">",
"      Tang LY, Rawsthorne P, Bernstein CN. Are perineal and luminal fistulas associated in Crohn's disease? A population-based study. Clin Gastroenterol Hepatol 2006; 4:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/6\">",
"      Hellers G, Bergstrand O, Ewerth S, Holmstr&ouml;m B. Occurrence and outcome after primary treatment of anal fistulae in Crohn's disease. Gut 1980; 21:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/7\">",
"      Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002; 8:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/8\">",
"      R&eacute;gimbeau JM, Panis Y, Marteau P, et al. Surgical treatment of anoperineal Crohn's disease: can abdominoperineal resection be predicted? J Am Coll Surg 1999; 189:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/9\">",
"      Lapidus A, Bernell O, Hellers G, L&ouml;fberg R. Clinical course of colorectal Crohn's disease: a 35-year follow-up study of 507 patients. Gastroenterology 1998; 114:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/10\">",
"      Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictors of Crohn's disease. Gastroenterology 2006; 130:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/11\">",
"      van Dongen LM, Lubbers EJ. Perianal fistulas in patients with Crohn's disease. Arch Surg 1986; 121:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/12\">",
"      Pescatori M, Interisano A, Basso L, et al. Management of perianal Crohn's disease. Results of a multicenter study in Italy. Dis Colon Rectum 1995; 38:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/13\">",
"      Nordgren S, Fasth S, Hult&eacute;n L. Anal fistulas in Crohn's disease: incidence and outcome of surgical treatment. Int J Colorectal Dis 1992; 7:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/14\">",
"      Williams DR, Coller JA, Corman ML, et al. Anal complications in Crohn's disease. Dis Colon Rectum 1981; 24:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/15\">",
"      Buchmann P, Keighley MR, Allan RN, et al. Natural history of perianal Crohn's disease. Ten year follow-up: a plea for conservatism. Am J Surg 1980; 140:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/16\">",
"      Sweeney JL, Ritchie JK, Nicholls RJ. Anal fissure in Crohn's disease. Br J Surg 1988; 75:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/17\">",
"      Akbar F, Maw A, Bhowmick A. Anal ulceration induced by nicorandil. BMJ 2007; 335:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/18\">",
"      Bonheur JL, Braunstein J, Korelitz BI, Panagopoulos G. Anal skin tags in inflammatory bowel disease: new observations and a clinical review. Inflamm Bowel Dis 2008; 14:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/19\">",
"      Fleshner PR, Schoetz DJ Jr, Roberts PL, et al. Anal fissure in Crohn's disease: a plea for aggressive management. Dis Colon Rectum 1995; 38:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/20\">",
"      Bernstein LH, Frank MS, Brandt LJ, Boley SJ. Healing of perineal Crohn's disease with metronidazole. Gastroenterology 1980; 79:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/21\">",
"      Brandt LJ, Bernstein LH, Boley SJ, Frank MS. Metronidazole therapy for perineal Crohn's disease: a follow-up study. Gastroenterology 1982; 83:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/22\">",
"      St&aring;hlberg D, B&aacute;r&aacute;ny F, Einarsson K, et al. Neurophysiologic studies of patients with Crohn's disease on long-term treatment with metronidazole. Scand J Gastroenterol 1991; 26:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/23\">",
"      Farkkila M, Seppala K. Long-term treatment of perianal or fistulous Crohn's disease with ciprofloxacin. Scand J Gastroenterol Suppl 1989; 24:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/24\">",
"      Singh B, George BD, Mortensen NJ. Surgical therapy of perianal Crohn's disease. Dig Liver Dis 2007; 39:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/25\">",
"      Schwartz DA, Loftus EV Jr, Tremaine WJ, et al. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology 2002; 122:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/26\">",
"      Lichtenstein GR, Hanauer SB, Sandborn WJ, Practice Parameters Committee of American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol 2009; 104:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/27\">",
"      Haggett PJ, Moore NR, Shearman JD, et al. Pelvic and perineal complications of Crohn's disease: assessment using magnetic resonance imaging. Gut 1995; 36:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/28\">",
"      Stoker J, Hussain SM, van Kempen D, et al. Endoanal coil in MR imaging of anal fistulas. AJR Am J Roentgenol 1996; 166:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/29\">",
"      Deen KI, Williams JG, Hutchinson R, et al. Fistulas in ano: endoanal ultrasonographic assessment assists decision making for surgery. Gut 1994; 35:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/30\">",
"      Orsoni P, Barthet M, Portier F, et al. Prospective comparison of endosonography, magnetic resonance imaging and surgical findings in anorectal fistula and abscess complicating Crohn's disease. Br J Surg 1999; 86:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/31\">",
"      Schwartz DA, Wiersema MJ, Dudiak KM, et al. A comparison of endoscopic ultrasound, magnetic resonance imaging, and exam under anesthesia for evaluation of Crohn's perianal fistulas. Gastroenterology 2001; 121:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/32\">",
"      Ng SC, Plamondon S, Gupta A, et al. Prospective evaluation of anti-tumor necrosis factor therapy guided by magnetic resonance imaging for Crohn's perineal fistulas. Am J Gastroenterol 2009; 104:2973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/33\">",
"      Maeda Y, Ng SC, Durdey P, et al. Randomized clinical trial of metronidazole ointment versus placebo in perianal Crohn's disease. Br J Surg 2010; 97:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/34\">",
"      Jakobovits J, Schuster MM. Metronidazole therapy for Crohn's disease and associated fistulae. Am J Gastroenterol 1984; 79:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/35\">",
"      Makowiec F, Jehle EC, Starlinger M. Clinical course of perianal fistulas in Crohn's disease. Gut 1995; 37:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/36\">",
"      Dejaco C, Harrer M, Waldhoer T, et al. Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease. Aliment Pharmacol Ther 2003; 18:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/37\">",
"      Thia KT, Mahadevan U, Feagan BG, et al. Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis 2009; 15:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/38\">",
"      Korelitz BI, Present DH. Favorable effect of 6-mercaptopurine on fistulae of Crohn's disease. Dig Dis Sci 1985; 30:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/39\">",
"      Jeshion WC, Larsen KL, Jawad AF, et al. Azathioprine and 6-mercaptopurine for the treatment of perianal Crohn's disease in children. J Clin Gastroenterol 2000; 30:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/40\">",
"      Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340:1398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/41\">",
"      Present DH, Lichtiger S. Efficacy of cyclosporine in treatment of fistula of Crohn's disease. Dig Dis Sci 1994; 39:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/42\">",
"      Hanauer SB, Smith MB. Rapid closure of Crohn's disease fistulas with continuous intravenous cyclosporin A. Am J Gastroenterol 1993; 88:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/43\">",
"      Ierardi E, Principi M, Rendina M, et al. Oral tacrolimus (FK 506) in Crohn's disease complicated by fistulae of the perineum. J Clin Gastroenterol 2000; 30:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/44\">",
"      Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/45\">",
"      Colombel JF, Schwartz DA, Sandborn WJ, et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut 2009; 58:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/46\">",
"      Sandborn WJ, Present DH, Isaacs KL, et al. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology 2003; 125:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/47\">",
"      Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995; 123:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/48\">",
"      Mahadevan U, Marion JF, Present DH. Fistula response to methotrexate in Crohn's disease: a case series. Aliment Pharmacol Ther 2003; 18:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/49\">",
"      Poggioli G, Laureti S, Pierangeli F, et al. Local injection of Infliximab for the treatment of perianal Crohn's disease. Dis Colon Rectum 2005; 48:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/50\">",
"      Hart AL, Plamondon S, Kamm MA. Topical tacrolimus in the treatment of perianal Crohn's disease: exploratory randomized controlled trial. Inflamm Bowel Dis 2007; 13:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/51\">",
"      Fukuda Y, Takazoe M, Sugita A, et al. Oral spherical adsorptive carbon for the treatment of intractable anal fistulas in Crohn's disease: a multicenter, randomized, double-blind, placebo-controlled trial. Am J Gastroenterol 2008; 103:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/52\">",
"      Vitton V, Gasmi M, Barthet M, et al. Long-term healing of Crohn's anal fistulas with fibrin glue injection. Aliment Pharmacol Ther 2005; 21:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/53\">",
"      Loungnarath R, Dietz DW, Mutch MG, et al. Fibrin glue treatment of complex anal fistulas has low success rate. Dis Colon Rectum 2004; 47:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/54\">",
"      Grimaud JC, Munoz-Bongrand N, Siproudhis L, et al. Fibrin glue is effective healing perianal fistulas in patients with Crohn's disease. Gastroenterology 2010; 138:2275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/55\">",
"      Regueiro M, Mardini H. Treatment of perianal fistulizing Crohn's disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement. Inflamm Bowel Dis 2003; 9:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/56\">",
"      Topstad DR, Panaccione R, Heine JA, et al. Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn's disease: a single center experience. Dis Colon Rectum 2003; 46:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/57\">",
"      Poritz LS, Rowe WA, Koltun WA. Remicade does not abolish the need for surgery in fistulizing Crohn's disease. Dis Colon Rectum 2002; 45:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/58\">",
"      Morrison JG, Gathright JB Jr, Ray JE, et al. Surgical management of anorectal fistulas in Crohn's disease. Dis Colon Rectum 1989; 32:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/59\">",
"      Scott HJ, Northover JM. Evaluation of surgery for perianal Crohn's fistulas. Dis Colon Rectum 1996; 39:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/60\">",
"      Thornton M, Solomon MJ. Long-term indwelling seton for complex anal fistulas in Crohn's disease. Dis Colon Rectum 2005; 48:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/61\">",
"      Sandborn WJ, Fazio VW, Feagan BG, et al. AGA technical review on perianal Crohn's disease. Gastroenterology 2003; 125:1508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/62\">",
"      Lichtenstein GR, Yan S, Bala M, et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005; 128:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/63\">",
"      Michelassi F, Melis M, Rubin M, Hurst RD. Surgical treatment of anorectal complications in Crohn's disease. Surgery 2000; 128:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/64\">",
"      Makowiec F, Jehle EC, Becker HD, Starlinger M. Perianal abscess in Crohn's disease. Dis Colon Rectum 1997; 40:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/65\">",
"      Pritchard TJ, Schoetz DJ Jr, Roberts PL, et al. Perirectal abscess in Crohn's disease. Drainage and outcome. Dis Colon Rectum 1990; 33:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/66\">",
"      Sangwan YP, Schoetz DJ Jr, Murray JJ, et al. Perianal Crohn's disease. Results of local surgical treatment. Dis Colon Rectum 1996; 39:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/67\">",
"      Ky A, Sohn N, Weinstein MA, Korelitz BI. Carcinoma arising in anorectal fistulas of Crohn's disease. Dis Colon Rectum 1998; 41:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25273/abstract/68\">",
"      Nikias G, Eisner T, Katz S, et al. Crohn's disease and colorectal carcinoma: rectal cancer complicating longstanding active perianal disease. Am J Gastroenterol 1995; 90:216.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4082 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-77.94.48.4-CAB5F750F4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_43_25273=[""].join("\n");
var outline_f24_43_25273=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2503026\">",
"      INITIAL PRESENTATION WITH PERIANAL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ANAL FISSURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Symptomatic relief",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Topical nitroglycerin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PERIANAL FISTULA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Asymptomatic patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Patients with mild to moderate symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Patients with severe or refractory disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Fibrin glue",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      ANORECTAL ABSCESSES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      ANAL STENOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      HEMORRHOIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      RISK OF ADENOCARCINOMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/4082\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4082|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/32/36355\" title=\"figure 1\">",
"      Parks classification fistulas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4082|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/14/35040\" title=\"picture 1\">",
"      Chronic anal fissure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/20/35136\" title=\"picture 2A\">",
"      Abscess fistulas and skin tags",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/3/29749\" title=\"picture 2B\">",
"      Perianal fistula Crohns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/16/22784\" title=\"picture 3\">",
"      Anal fissure and ulcer Crohns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/62/24546\" title=\"picture 4\">",
"      Perianal fistulas and ulcers",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29559?source=related_link\">",
"      Adalimumab for treatment of Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/24/34181?source=related_link\">",
"      Anal fissure: Clinical manifestations, diagnosis, prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/1/15384?source=related_link\">",
"      Anal fissure: Medical and surgical management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/34/20008?source=related_link\">",
"      Antibiotics for treatment of inflammatory bowel diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=related_link\">",
"      Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/31/7673?source=related_link\">",
"      Immunomodulator therapy in Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44105?source=related_link\">",
"      Infliximab in Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/51/5946?source=related_link\">",
"      Operative management of anorectal fistulas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19305?source=related_link\">",
"      Overview of the medical management of mild to moderate Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6329?source=related_link\">",
"      Overview of the medical management of severe or refractory Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/31/44529?source=related_link\">",
"      Patient information: Anal fissure (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/40/24196?source=related_link\">",
"      Patient information: Crohn's disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/56/10115?source=related_link\">",
"      Patient information: Crohn's disease in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26246?source=related_link\">",
"      Perianal abscess: Clinical manifestations, diagnosis, treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/25/39319?source=related_link\">",
"      The role of imaging tests in the evaluation of anal abscesses and fistulas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/61/6105?source=related_link\">",
"      Treatment of hemorrhoids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_43_25274="Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis";
var content_f24_43_25274=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/43/25274/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/43/25274/contributors\">",
"     Michael J Burns, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/43/25274/contributors\">",
"     Scott L Friedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/43/25274/contributors\">",
"     Anne M Larson, MD, FACP, AGAF",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/43/25274/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/43/25274/contributors\">",
"     Stephen J Traub, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/43/25274/contributors\">",
"     Michele Burns Ewald, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/43/25274/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/43/25274/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/43/25274/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since its clinical introduction in 1955,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    (N-acetyl-p-aminophenol; APAP; paracetamol) has become the most widely used analgesic-antipyretic in the United States. Acetaminophen is a component of hundreds of over-the-counter and prescription medications used worldwide.",
"   </p>",
"   <p>",
"    Although the drug is remarkably safe when taken at usual therapeutic doses, overdose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    has been recognized since 1966 to cause fatal and nonfatal hepatic necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/1\">",
"     1",
"    </a>",
"    ]. It is suspected that even repeated therapeutic or slightly excessive doses can be hepatotoxic in susceptible individuals, such as alcoholics [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/2-7\">",
"     2-7",
"    </a>",
"    ]. Acetaminophen poisoning has become the most common cause of acute liver failure in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/8-12\">",
"     8-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathophysiology, clinical manifestations, and diagnosis of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    intoxication will be reviewed here. Treatment of this condition is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32937?source=see_link\">",
"     \"Acetaminophen (paracetamol) poisoning in adults: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     Acetaminophen",
"    </a>",
"    is widely available, and lay people commonly underestimate its toxicity. In addition, a substantial percentage of patients ingest excessive amounts of acetaminophen because they misunderstand dosing directions or fail to recognize that acetaminophen is found in more than one medication they are using [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/13\">",
"     13",
"    </a>",
"    ]. Such errors occur most often among patients with limited literacy or heavy acetaminophen use.",
"   </p>",
"   <p>",
"    Not surprisingly,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    remains a major cause of overdose and overdose-related liver failure and death in the United States and many other countries [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/8,14\">",
"     8,14",
"    </a>",
"    ]. A national network established to track cases of acute liver failure in the United States found that nearly half the episodes are attributable to acetaminophen, and such cases appear to be increasing as a percentage of all acute liver failure events [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/9,15\">",
"     9,15",
"    </a>",
"    ]. Data from this group demonstrate that intentional (suicidal) and unintentional (chronic) poisonings account equally for cases of acetaminophen-associated hepatic failure [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective review of all cases of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    overdose that occurred over 10 years in the Calgary region of Canada noted the following [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Of 1543 patients, 70 (4.5 percent) developed hepatotoxicity and 15 died during their initial hospital admission.",
"     </li>",
"     <li>",
"      Risk factors for hepatotoxicity included unintentional overdose (OR 5.18; 95% CI 3.00-8.95), alcohol abuse (OR 2.21; 95% CI 1.30-3.76), and underlying liver disease (OR 3.50; 95% CI 1.57-7.77).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PHARMACOKINETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     Acetaminophen",
"    </a>",
"    is available in both immediate-release and sustained-release formulations (",
"    <a class=\"graphic graphic_table graphicRef79854 \" href=\"UTD.htm?30/9/30876\">",
"     table 1",
"    </a>",
"    ). The therapeutic dose is 10 to 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose in children and 325 to 1000 mg per dose in adults, given every four to six hours, with a maximum recommended daily dose of 80",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    in children or 4 g in adults. The toxic dose may vary among individuals according to baseline glutathione levels and other factors (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Clinical factors influencing toxicity'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Toxicity is unlikely to result from a single dose of less than 150",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      in a child or 7.5 to 10 g for an adult [",
"      <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Toxicity is likely to occur with single ingestions greater than 250",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      or those greater than 12 g over a 24-hour period [",
"      <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/18,19\">",
"       18,19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Virtually all patients who ingest doses in excess of 350",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      develop severe liver toxicity (defined as peak aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels greater than 1000",
"      <span class=\"nowrap\">",
"       IU/L)",
"      </span>",
"      unless appropriately treated [",
"      <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     Acetaminophen",
"    </a>",
"    is rapidly and completely absorbed from the gastrointestinal tract. Serum concentrations peak between one-half and two hours after an oral therapeutic dose [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/20\">",
"     20",
"    </a>",
"    ]. Peak serum concentrations are reached within four hours following overdose of immediate-release preparations, but may be delayed beyond four hours when drugs that delay gastric emptying (eg, opiates, anticholinergic agents) are coingested or following overdose of extended releases preparations [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. Therapeutic serum concentrations range from 10 to 20",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    (65 to 130",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"   </p>",
"   <p>",
"    Elimination half-lives range from two to four hours for all",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    preparations, but the elimination phase may be delayed in onset for extended-release preparations due to prolonged tablet dissolution and absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/22,24\">",
"     22,24",
"    </a>",
"    ]. Half-lives greater than four hours have been noted in patients with hepatotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     BIOCHEMICAL TOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;At therapeutic doses, 90 percent of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    is metabolized in the liver to sulfate and glucuronide conjugates, which are then excreted in the urine [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/20,26,27\">",
"     20,26,27",
"    </a>",
"    ]. Approximately 2 percent is excreted in the urine unchanged. The remaining acetaminophen is metabolized via the hepatic cytochrome P450 (CYP2E1, CYP1A2, CYP3A4 subfamilies) mixed function oxidase pathway into a toxic, highly reactive, electrophilic intermediate, N-acetyl-p-benzoquinoneimine (NAPQI) (",
"    <a class=\"graphic graphic_figure graphicRef68213 \" href=\"UTD.htm?20/49/21279\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/5,27-30\">",
"     5,27-30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Appropriate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    doses produce a small amount of NAPQI which is rapidly conjugated with hepatic glutathione, forming nontoxic cysteine and mercaptate compounds that are excreted in the urine [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/26,31\">",
"     26,31",
"    </a>",
"    ]. However, with toxic doses of a acetaminophen the sulfation and glucuronidation pathways are saturated, and more acetaminophen is metabolized to NAPQI via the cytochrome P450 enzymes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/32\">",
"     32",
"    </a>",
"    ]. When hepatic glutathione stores are depleted by approximately 70 to 80 percent, NAPQI begins to react with hepatocytes, and injury ensues [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/18,26,33,34\">",
"     18,26,33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    NAPQI arylates and binds covalently to the cysteine groups on hepatic macromolecules, forming NAPQI-protein adducts [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. This process is irreversible and leads to oxidative injury and hepatocellular centrilobular necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. Although not fully characterized, lipid peroxidation and mitochondrial injury likely play a role in the progression of hepatocellular injury [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/15,41\">",
"     15,41",
"    </a>",
"    ]. In addition, it appears that the release of cytokines and reactive nitrogen and oxygen species from damaged hepatocytes also play a role in the spread of hepatic injury. Cytokine release from hepatocytes may initiate a secondary inflammatory response from Kupffer cells and other inflammatory cells, extending the zone of hepatic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/42-46\">",
"     42-46",
"    </a>",
"    ]. This secondary injury occurs during stage II of clinical toxicity. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Clinical manifestations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL FACTORS INFLUENCING TOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver damage from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    ingestion can occur in four circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Excessive intake of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"     </li>",
"     <li>",
"      Excessive cytochrome P450 activity",
"     </li>",
"     <li>",
"      Decreased capacity for glucuronidation or sulfation",
"     </li>",
"     <li>",
"      Depletion of glutathione stores",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of factors may influence the propensity of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    to cause hepatotoxicity through the mechanisms listed above, including concomitant use of alcohol or other drugs, comorbid illnesses, advancing age, genetic makeup, and nutritional status [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Acute alcohol ingestion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute alcohol ingestion is",
"    <strong>",
"     NOT",
"    </strong>",
"    a risk factor for hepatotoxicity and may even be protective by competing with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    for CYP2E1 and, thereby, decreasing the amount of NAPQI produced [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/47-50\">",
"     47-50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Chronic alcohol ingestion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of chronic alcohol ingestion in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    -induced hepatotoxicity remains contentious. Chronic alcohol ingestion increases CYP2E1 activity two-fold and depletes glutathione levels [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/3,51,52\">",
"     3,51,52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Single overdose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic alcoholics do NOT appear to be at increased risk compared with non-alcoholics for developing hepatotoxicity following a SINGLE overdose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    and management need not be altered for this patient group [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/19,53\">",
"     19,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one multicenter study of 2540 patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    overdose, chronic alcohol use did not increase the incidence of hepatotoxicity in low-risk patients (those treated with NAC within eight hours of ingestion or with acetaminophen concentration less than the probable hepatic toxicity line of the original Rumack-Matthew nomogram) (",
"    <a class=\"graphic graphic_figure graphicRef61338 \" href=\"UTD.htm?26/10/26798\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In another report of 560 patients with severe",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    -induced hepatotoxicity, a history of excessive alcohol consumption was not associated with a significantly worsened prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/19\">",
"     19",
"    </a>",
"    ]. There is a single reported case of a chronic alcohol user in whom hepatotoxicity developed despite a low predicted risk for this complication by the modified Rumack-Matthew nomogram [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Multiple overdoses",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to chronic alcoholics with an isolated ingestion, chronic alcoholics appear to be at increased risk for hepatotoxicity following ingestion of multiple supratherapeutic doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/2-7,56,57\">",
"     2-7,56,57",
"    </a>",
"    ]. Delayed recognition of toxicity and continued use of the drug likely account for much of the morbidity in this patient population [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/7\">",
"     7",
"    </a>",
"    ]. Alcohol acts at least in part by induction of CYP2E1, which results in the shunting of a greater fraction of acetaminophen through the CYP2E1 pathway and enhanced generation of NAPQI [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. The net effect is an increased clearance rate of acetaminophen [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/58\">",
"     58",
"    </a>",
"    ] and associated increased risk for hepatotoxicity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/5/30807?source=see_link\">",
"     \"Pathogenesis of alcoholic liver disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to increased CYP2E1 pathway activity, several other factors may predispose alcoholics to severe",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    -induced hepatotoxicity. The chronic alcoholic is more often malnourished, more likely to have a period of recent fasting, and more likely to have depleted hepatic glutathione stores than the nonalcoholic, all of which predispose to hepatic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/5,57,59-61\">",
"     5,57,59-61",
"    </a>",
"    ]. Chronic alcoholics may also have a decreased capacity to synthesize a mitochondrial glutathione transport protein, thus enhancing susceptibility of mitochondria to NAPQI [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/59,62\">",
"     59,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of chronic ethanol ingestion in conjunction with repeated, therapeutic doses (up to 4",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    is controversial. The question of increased risk was raised in one report of 161 regular users of alcohol who developed hepatotoxicity following acetaminophen ingestion with therapeutic intent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/3\">",
"     3",
"    </a>",
"    ]. Although according to patient reports 54 percent had ingested 6 grams or less per day and 30 percent had taken less than 4",
"    <span class=\"nowrap\">",
"     g/day,",
"    </span>",
"    the overall mortality rate reached 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite this concerning finding, there is no evidence from prospective controlled trials that therapeutic doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    cause hepatotoxicity in chronic alcohol users [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/7,53,61-65\">",
"     7,53,61-65",
"    </a>",
"    ]. In one prospective, double-blind, randomized study of 201 alcoholics given maximal therapeutic doses (total 4",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    or placebo for two days showed no statistical difference in aspartate aminotransferase (AST) or alanine aminotransferase (ALT) concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/65\">",
"     65",
"    </a>",
"    ]. Similarly, a smaller controlled prospective study of 20 patients with chronic liver disease (including alcoholic cirrhosis) did not develop hepatotoxicity when given acetaminophen at 4",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    for two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Chronic liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with chronic liver disease who do not regularly ingest alcohol do NOT appear to be at increased risk for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    -induced hepatic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/7,64,66\">",
"     7,64,66",
"    </a>",
"    ]. Although the acetaminophen elimination half-life in this patient population may be prolonged, accumulation of the drug does not occur with repeated administration [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/64\">",
"     64",
"    </a>",
"    ]. More importantly, cytochrome P450 enzyme activity is low and cannot be induced in this patient population, which confers hepatoprotection following overdose [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concomitant use of drugs that induce CYP2E1 enzymes can cause hepatotoxicity in the absence of overt",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    overdose, and may worsen the outcome of an intentional overdose. Examples of medications which alter CYP2E1 activity include anticonvulsants (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ) and antituberculosis drugs (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/66,68,69\">",
"     66,68,69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Drugs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    may potentiate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    hepatotoxicity by competing for glucuronidation pathways, resulting in increased CYP2E1-dependent metabolism of acetaminophen [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/70\">",
"     70",
"    </a>",
"    ]. Herbal supplements may potentially amplify acetaminophen-induced injury [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/71\">",
"     71",
"    </a>",
"    ]. Patients should be questioned specifically about the use of herbal supplements since they are widely used, but often not mentioned during a routine medical interview.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Nutritional status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malnutrition and a period of fasting may predispose to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    hepatotoxicity, but evidence is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/5,62,72\">",
"     5,62,72",
"    </a>",
"    ]. Hepatic glucuronidation is normally dependent upon hepatic carbohydrate reserves. In the fasting or malnourished state, glucuronidation of acetaminophen is reduced which leads to enhanced microsomal metabolism and increased production of the toxic NAPQI metabolite [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/5,73,74\">",
"     5,73,74",
"    </a>",
"    ]. Depleted glutathione stores, also associated with the fasting and malnourished state, compromise detoxification of NAPQI and predispose to hepatic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/75\">",
"     75",
"    </a>",
"    ]. In one study, recent fasting appeared to be increase hepatotoxicity in patients with a moderate overdose (4 to 10 grams of acetaminophen within 24 hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/5\">",
"     5",
"    </a>",
"    ]. Patients at greatest risk appear to be those that consume repeated excessive doses, not a single overdose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymorphisms exist in the cytochrome isoenzymes that contribute to diminished or excessive oxidative metabolism of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. The clinical relevance of these polymorphisms is unknown. Impaired glucuronidation secondary to Gilbert's syndrome appears to enhance toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Older patients appear more likely to develop hepatotoxicity following acute overdose whereas children less than five years old appear less susceptible to toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/15,79-81\">",
"     15,79-81",
"    </a>",
"    ]. Young children are probably protected via an increased supply and regeneration of glutathione and greater activity of conjugation enzymes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. However, following repeated excessive acetaminophen doses, young children are no less susceptible to hepatic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Tobacco",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tobacco smoke contains CYP1A2 inducers and increases oxidative metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. One review found tobacco use to be an independent risk factor for mortality following",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    overdose independent of the amount of tobacco consumed [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/87\">",
"     87",
"    </a>",
"    ]. Mortality was greatest in smokers who also drink alcohol.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Pattern of use",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pattern of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    use is an important consideration when assessing the risk for subsequent toxicity. Patients who accidentally poison themselves with repeated excessive doses in an attempt to relieve pain or treat fever are more likely to have established risk factors for hepatotoxicity (eg, fasting, chronic ethanol use) and are more likely to present late, when the toxic effects of acetaminophen are already established. In one study of 71 patients admitted with acetaminophen toxicity, patients in the accidental-overdose group had higher rates of severe hepatotoxicity, hepatic coma, and death than those who attempted suicide, even though the latter had ingested more acetaminophen [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike most other causes of hepatitis,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    -induced hepatitis is acute in onset, progresses rapidly, is characterized by marked elevation of plasma aminotransferases (&gt;3000",
"    <span class=\"nowrap\">",
"     IU/L),",
"    </span>",
"    and is associated with a rising PT. Chronic acetaminophen poisoning in the alcohol user is also characterized by markedly elevated aminotransferases (&gt;3000",
"    <span class=\"nowrap\">",
"     IU/L),",
"    </span>",
"    combined with hypovolemia, jaundice, coagulopathy, hypoglycemia, and acute renal failure in greater than 50 percent of these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/2,3,29,88\">",
"     2,3,29,88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other diagnoses that should be considered in patients with evidence of hepatic dysfunction include alcoholic hepatitis, other drug- or toxin-induced hepatitis, viral hepatitis, hepatobiliary disease, Reye's syndrome, and ischemic hepatitis (\"shock liver\"), which usually follows a period of severe prolonged hypotension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/18/34090?source=see_link\">",
"     \"Approach to the patient with abnormal liver biochemical and function tests\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dramatic elevations in the serum total bilirubin level (&gt;10",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    can result in a",
"    <strong>",
"     false positive",
"    </strong>",
"    serum assay for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    in patients with acute viral hepatitis, which may delay recognition of the underlying problem [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/89\">",
"     89",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7591?source=see_link\">",
"     \"Overview of hepatitis A virus infection in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42279?source=see_link\">",
"     \"Serologic diagnosis of hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unlike acute",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    poisoning, alcoholic hepatitis and chronic acetaminophen poisoning in the alcohol user have an AST to ALT ratio greater than two [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Aminotransferase values are also markedly lower in patients with alcoholic hepatitis, and rarely exceed 500",
"    <span class=\"nowrap\">",
"     IU/L.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/42/21162?source=see_link\">",
"     \"Clinical manifestations and diagnosis of alcoholic fatty liver disease and alcoholic cirrhosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5446?source=see_link\">",
"     \"Patterns of plasma aspartate and alanine aminotransferase levels with and without liver disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial manifestations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    poisoning are often mild and nonspecific, and do not reliably predict subsequent hepatotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/53,90\">",
"     53,90",
"    </a>",
"    ]. However, physicians must promptly recognize acetaminophen poisoning in order to minimize subsequent morbidity and mortality. The clinical course of poisoning is often divided in four sequential stages.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Stage I (0.5 to 24 hours)",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the first 24 hours after overdose, patients often manifest nausea, vomiting, diaphoresis, pallor, lethargy, and malaise. Some patients remain asymptomatic. Laboratory studies are typically normal. Central nervous system depression and elevated anion gap metabolic acidosis are rarely seen after massive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    overdose [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/91\">",
"     91",
"    </a>",
"    ]. Such symptoms in acetaminophen-poisoned patients are usually due to coingestants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Stage II (24 to 72 hours)",
"    </span>",
"    &nbsp;&mdash;&nbsp;From 24 to 72 hours after ingestion, the clinical and laboratory evidence of hepatotoxicity and, occasionally, nephrotoxicity become evident. (See",
"    <a class=\"local\" href=\"#H1984922420\">",
"     'Acute kidney injury (acute renal failure)'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Initially, stage I symptoms usually resolve and patients appear to improve clinically while subclinical elevations of hepatic aminotransferases (AST, ALT) occur. Occasionally, aminotransferases may rise as early as 8 to 12 hours after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    ingestion in severely poisoned patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Of patients that develop hepatic injury, over one half will demonstrate aminotransferase elevation within 24 hours and all have elevations by 36 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/92\">",
"     92",
"    </a>",
"    ]. As stage II progresses, patients develop right upper quadrant pain, with liver enlargement and tenderness. Elevations of prothrombin time (PT) and total bilirubin, oliguria, and renal function abnormalities may become evident.",
"   </p>",
"   <p>",
"    Acute pancreatitis has been described in case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/93,94\">",
"     93,94",
"    </a>",
"    ]. In some patients, concurrent alcohol use contributes to both hepatotoxicity and pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Stage III (72 to 96 hours)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver function abnormalities peak from 72 to 96 hours after ingestion. The systemic symptoms of stage I reappear in conjunction with jaundice, confusion (hepatic encephalopathy), a marked elevation in hepatic enzymes, hyperammonemia, and a bleeding diathesis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63610 \" href=\"UTD.htm?36/3/36914\">",
"     image 1",
"    </a>",
"    ). Signs of severe hepatotoxicity include plasma ALT and AST levels that often exceed 10,000",
"    <span class=\"nowrap\">",
"     IU/L,",
"    </span>",
"    prolongation of the PT or INR, hypoglycemia, lactic acidosis, and a total bilirubin concentration above 4.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (primarily indirect). Acute renal failure occurs in 10 to 25 percent of patients with significant hepatotoxicity and in more than 50 percent of those with frank hepatic failure [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/29,96,97\">",
"     29,96,97",
"    </a>",
"    ]. Death most commonly occurs in this stage, usually from multiorgan system failure [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1984922420\">",
"     'Acute kidney injury (acute renal failure)'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Stage IV (four days to two weeks)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who survive stage III enter a recovery phase that usually begins by day four and is complete by seven days after overdose [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/53\">",
"     53",
"    </a>",
"    ]. Recovery can be slower in severely ill patients; symptoms and laboratory values may not normalize for several weeks. Histologic changes in the liver vary from cytolysis to centrilobular necrosis. The centrilobular region (zone III) is preferentially involved because it is the area of greatest concentration of CYP2E1 and therefore the site of maximal production of NAPQI. Histologic recovery lags behind clinical recovery and may take up to three months. When recovery occurs, it is complete; chronic hepatic dysfunction is not a sequela of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    poisoning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1984922420\">",
"    <span class=\"h2\">",
"     Acute kidney injury (acute renal failure)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of renal dysfunction is related to the severity of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    ingestion. Renal impairment has been estimated to occur in less than 2 percent of all patients (including those with minimal disease), 5 percent of cases with liver involvement but no hepatic failure, 10 percent of severe poisonings, and as many as 53 percent of cases with acute hepatic failure [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/97,98\">",
"     97,98",
"    </a>",
"    ]. It is possible in the last setting that a hepatorenal-type syndrome, as well as direct toxicity, contributes to the development of renal failure.",
"   </p>",
"   <p>",
"    Acute kidney injury is manifested by elevations of blood urea nitrogen and creatinine along with proteinuria, hematuria, and granular and epithelial cell casts on urinalysis.",
"   </p>",
"   <p>",
"    Acute kidney injury is due primarily to acute tubular necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/88,99\">",
"     88,99",
"    </a>",
"    ]. Vascular endothelial damage also can occur, so that both direct toxicity and ischemia may contribute to the tubular injury [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Renal function spontaneously returns to the previous baseline within one to four weeks, although dialysis may be required during the acute episode [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/97\">",
"     97",
"    </a>",
"    ]. There is no evidence that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/1/20504?source=see_link\">",
"     acetylcysteine",
"    </a>",
"    , which is given to minimize hepatotoxicity, has any protective effect on the kidney.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     General approach and serum acetaminophen concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;A serum",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    level must be obtained in every patient suspected of an intentional overdose.",
"   </p>",
"   <p>",
"    The general approach to any poisoned patient should include the following elements:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Whenever possible, evaluation should include identification of the agents involved, assessment of severity, and prediction of toxicity. In all patients with suspected",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      overdose, a history should be obtained to elicit the dose, intent of use (ie, suicidal or not), pattern of use (eg, single or repeated doses), and time of the ingestion, the presence of coingestants, and the existence of comorbid conditions that may predispose to the development of hepatic injury (eg, alcohol use, Gilbert's disease, anticonvulsant drug use, recent fasting). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical factors influencing toxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients with a clear history of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      overdose should undergo measurement of serum acetaminophen concentration. If any doubt exists about the time of ingestion, a serum concentration should be obtained immediately at the time of presentation. A serum concentration should also be obtained four hours following the time of acute ingestion or presentation.",
"      <br/>",
"      <br/>",
"      In those with established toxicity, or those predicted to develop toxicity based on history and initial serum acetaminophen concentration, additional laboratory tests should include electrolytes, BUN and creatinine, serum total bilirubin level, prothrombin time with INR, AST, ALT, amylase, and urinalysis. In patients with intentional ingestions or unreliable histories, toxic screening of blood and urine for other ingested drugs should be performed. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=see_link\">",
"       \"General approach to drug poisoning in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Management consists of supportive care, prevention of drug absorption, and, when appropriate, the administration of antidotes and enhancement of drug elimination. Treatment of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      poisoning is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32937?source=see_link\">",
"       \"Acetaminophen (paracetamol) poisoning in adults: Treatment\"",
"      </a>",
"      .) and also (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16297?source=see_link\">",
"       \"Gastrointestinal decontamination of poisoned adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26695?source=see_link\">",
"       \"Enhanced elimination of poisons\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Evaluation after acute overdose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of toxicity is best predicted by relating the time of ingestion to the serum",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    concentration. The dose history should not be used as studies have found no correlation between the amount of acetaminophen reportedly ingested and the serum concentration measured [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/100,101\">",
"     100,101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After a single acute overdose of an immediate-release preparation, a serum",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    concentration should be drawn four and 24 hours after presentation. If the ingestion was more than four hours prior to presentation, it should be drawn immediately. The level should be evaluated according to the modified Rumack-Matthew nomogram to determine the need for NAC therapy (",
"    <a class=\"graphic graphic_figure graphicRef83590 \" href=\"UTD.htm?24/56/25472\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/102\">",
"     102",
"    </a>",
"    ]. Serum concentrations drawn before four hours may not represent peak values, and should not be used [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/53,103\">",
"     53,103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The original nomogram, based on large numbers of overdose patients not treated with antidote, relates serum",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    concentration to the time of ingestion as a predictor of hepatotoxicity (",
"    <a class=\"graphic graphic_figure graphicRef61338 \" href=\"UTD.htm?26/10/26798\">",
"     figure 2",
"    </a>",
"    ). Without antidotal therapy, patients with serum acetaminophen concentrations above the line joining 200",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    (1320",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    at 4 hours and 25",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    (165",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    at 16 hours (\"probable hepatic toxicity\") have a 60 percent incidence of severe hepatotoxicity (AST greater than 1000",
"    <span class=\"nowrap\">",
"     IU/L)",
"    </span>",
"    and a mortality rate of 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/18,104\">",
"     18,104",
"    </a>",
"    ]. Untreated patients with serum acetaminophen concentrations above the line joining 300",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    (1980",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    at 4 hours and 37.5",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    (250",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    at 16 hours (\"high hepatic toxicity\") have a 90 percent incidence of severe hepatotoxicity and a mortality rate of up to 24 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/18,104\">",
"     18,104",
"    </a>",
"    ]. As originally reported, patients with serum acetaminophen concentrations below the \"probable hepatic toxicity\" line did not develop severe hepatotoxicity and no fatalities were reported [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/18,102,104\">",
"     18,102,104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients in the United States with serum",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    concentrations above the line connecting 150",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    (990",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    at 4 hours and 18.8",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    (125",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    at 16 hours are considered at \"possible risk\" for hepatotoxicity and treatment with NAC is standard (",
"    <a class=\"graphic graphic_figure graphicRef83590 \" href=\"UTD.htm?24/56/25472\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/47,105\">",
"     47,105",
"    </a>",
"    ]. This modified treatment line is 25 percent lower than the original treatment line (\"probable hepatic toxicity\"), which is still used in Australia, Canada, and Great Britain. This margin of safety was created to allow for variations in acetaminophen measurements among laboratories and possible errors in the estimated time of ingestion. The incidence of nomogram failure using the modified line is extraordinary small [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/55\">",
"     55",
"    </a>",
"    ]. The 25 percent margin of safety also likely protects susceptible patients who are at higher risk for developing hepatotoxicity (eg, alcohol users). This is no evidence to support lowering the treatment line further for these patients, as suggested by some authorities [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/29,106,107\">",
"     29,106,107",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even with NAC treatment, severe hepatic toxicity (AST &gt;1000 IU) may occasionally occur when patients have serum",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    concentrations below the \"possible hepatic toxicity\" line. In one study of 2023 patients treated with oral NAC for acute acetaminophen overdose, the incidence of severe hepatotoxicity was 0 to 3 percent for those patients with serum acetaminophen concentrations below the \"possible hepatic toxicity\" line [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/62,105\">",
"     62,105",
"    </a>",
"    ]. There were no deaths in this group of treated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is presently insufficient experience to know whether the Rumack-Matthew nomogram can accurately assess risk following acute overdose of sustained-release",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    products. Some authorities (including the manufacturer) recommend that both a four- and eight-hour serum acetaminophen concentration be measured and treatment with NAC initiated if either concentration is above the \"possible hepatic toxicity\" line of the nomogram [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/22,108\">",
"     22,108",
"    </a>",
"    ]. It is likely that a single acetaminophen concentration plotted on the nomogram and below the treatment line is adequate to exclude the need for NAC treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/53\">",
"     53",
"    </a>",
"    ]. Until more clinical experience has been gained, our recommendation is to follow the conservative approach of the manufacturer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32937?source=see_link\">",
"     \"Acetaminophen (paracetamol) poisoning in adults: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Evaluation after repeated (chronic) overdose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosis of chronic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    intoxication is often difficult and requires the combination of an astute history and recognition of typical clinical and laboratory abnormalities. Signs and symptoms are insidious in onset, often nonspecific, and easily confused with alternative diagnoses (eg, viral syndrome). When inquiring about potentially toxic drugs, clinicians should ask about acetaminophen, including specific questions about dosing and the pattern of use. Acetaminophen serum concentrations are frequently therapeutic in the chronic overdose population and concentrations do not correlate with toxicity as with the acute overdose [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/3,6,56,109\">",
"     3,6,56,109",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When the diagnosis of chronic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    intoxication is suspected, the goal of evaluation is to identify patients who need NAC treatment based upon a combination of historical, clinical, and laboratory data. Patients are at increased risk for developing acetaminophen-induced hepatotoxicity if they have any of the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ingestion of greater than 7.5 to 10 g of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      over 24 hours, or ingestion of greater than 4 grams over 24 hours",
"      <strong>",
"       AND",
"      </strong>",
"      have an increased susceptibility to hepatotoxicity (eg, chronic alcohol use, fasting, use of P450-inducing drugs) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/17,53\">",
"       17,53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Liver tenderness, jaundice, or are ill-appearing.",
"     </li>",
"     <li>",
"      Supratherapeutic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      concentrations (greater than 20",
"      <span class=\"nowrap\">",
"       mcg/mL,",
"      </span>",
"      or 130",
"      <span class=\"nowrap\">",
"       micromol/L).",
"      </span>",
"      Patients with a history of chronic, excessive acetaminophen ingestion should be considered to have acetaminophen-induced hepatotoxicity when aminotransferases are elevated, regardless of the measured serum acetaminophen concentration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment with NAC is recommended for all patients with liver tenderness, elevations of aminotransferases, supratherapeutic serum",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    concentrations (greater than 20",
"    <span class=\"nowrap\">",
"     mcg/mL,",
"    </span>",
"    130",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    and those with history of excessive ingestion, risk factors for toxicity, and acetaminophen concentrations &gt;10",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    (65",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"    If a patient has a detectable acetaminophen concentration but is without signs, symptoms, or risk factors for toxicity and without elevations of aminotransferases, then treatment is likely not necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/53\">",
"     53",
"    </a>",
"    ]. If the serum acetaminophen concentration is undetectable and aminotransferases are normal, NAC therapy is not necessary. Treatment is clearly recommended if serum acetaminophen concentrations are potentially toxic by the nomogram with respect to the time of the last dose. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32937?source=see_link\">",
"     \"Acetaminophen (paracetamol) poisoning in adults: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    overdose, including antidotal treatment with N-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/1/20504?source=see_link\">",
"     acetylcysteine",
"    </a>",
"    (NAC), is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32937?source=see_link\">",
"     \"Acetaminophen (paracetamol) poisoning in adults: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The outcome of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    intoxication is nearly always good if the antidote, N-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/1/20504?source=see_link\">",
"     acetylcysteine",
"    </a>",
"    (NAC), is administered in a timely fashion. No deaths have been reported in any of the large studies of acetaminophen overdose provided NAC was given within 10 hours of ingestion, regardless of the initial serum acetaminophen concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/104,105,110\">",
"     104,105,110",
"    </a>",
"    ]. As an example, one study of 333 consecutive acetaminophen overdose cases found that hepatotoxicity occurred in only 4 percent of patients and mortality was less than 1 percent when NAC was rapidly administered [",
"    <a class=\"abstract\" href=\"UTD.htm?24/43/25274/abstract/111\">",
"     111",
"    </a>",
"    ]. Thus, when fulminant hepatic failure and death occur from acetaminophen poisoning, they result from a delay in seeking medical attention, in recognition of poisoning, or in the institution of appropriate therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13755278\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional poison control centers in the United States are available at all times for consultation on patients who are critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medical toxicologists available for bedside consultation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inpatient care. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. The World Health Organization provides a listing of international poison centers at its website:",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/49/33554?source=see_link\">",
"       \"Patient information: Acetaminophen poisoning (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42644071\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important elements of the presentation and diagnosis of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    overdose are described below. Management of acetaminophen overdose is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32937?source=see_link\">",
"     \"Acetaminophen (paracetamol) poisoning in adults: Treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/51/13114?source=see_link\">",
"     \"Management of acetaminophen (paracetamol) poisoning in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       Acetaminophen",
"      </a>",
"      can be fatal in overdose, but the lay public often under-appreciates the potential dangers of this medication. The therapeutic dose is 10 to 15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per dose in children and 325 to 1000 mg per dose in adults, with a maximum recommended daily dose of 80",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      in children or 4 g in adults. The toxic dose varies among individuals, but toxicity is unlikely to result from a single dose of less than 150",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      in a child or 7.5 to 10 g for an adult. Toxicity",
"      <strong>",
"       IS",
"      </strong>",
"      likely to occur with single ingestions greater than 250",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      or those greater than 12 g over a 24-hour period. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Pharmacokinetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       Acetaminophen",
"      </a>",
"      is rapidly and completely absorbed from the gastrointestinal tract. Serum concentrations peak between one-half and two hours after an oral therapeutic dose. Peak serum concentrations are reached within four hours following overdose of immediate-release preparations but may be delayed when drugs that slow gastric emptying (eg, opiates, anticholinergic agents) are coingested or following overdose of extended release preparations. The biochemical pathways leading to toxicity are described in the text. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pharmacokinetics'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Biochemical toxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical factors that can predispose patients to injury from",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      ingestion include chronic alcohol ingestion, medications that affect the CYP2E1 enzyme system of the liver, malnutrition, and older age. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical factors influencing toxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Unlike most other causes of hepatitis,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      -induced hepatitis is acute in onset, progresses rapidly, is characterized by marked elevation of plasma aminotransferases (&gt;3000",
"      <span class=\"nowrap\">",
"       IU/L),",
"      </span>",
"      and is associated with a rising prothrombin time. Chronic acetaminophen poisoning in the alcohol user is also characterized by markedly elevated aminotransferases (&gt;3000",
"      <span class=\"nowrap\">",
"       IU/L),",
"      </span>",
"      combined with hypovolemia, jaundice, coagulopathy, hypoglycemia, and acute renal failure in greater than 50 percent of these patients. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial manifestations of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      poisoning are often mild and nonspecific, and do not reliably predict subsequent hepatotoxicity. Thus, measurement of the serum acetaminophen concentration is critical whenever overdose is suspected. The symptoms and signs of the four stages of acetaminophen overdose are described in the text. Severe overdose can result in liver failure. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk of toxicity is best predicted by relating the time of ingestion to the serum",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      concentration. Therapeutic serum concentrations range from 10 to 20",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"      (65 to 130",
"      <span class=\"nowrap\">",
"       micromol/L).",
"      </span>",
"      After a single acute overdose of an immediate-release preparation, a serum acetaminophen concentration should be drawn 4 and 24 hours after presentation. If the ingestion was more than four hours prior to presentation, it should be drawn immediately. The level should be evaluated according to the modified Rumack-Matthew nomogram to determine the need for NAC therapy (",
"      <a class=\"graphic graphic_figure graphicRef83590 \" href=\"UTD.htm?24/56/25472\">",
"       figure 3",
"      </a>",
"      ). Use of the nomogram in the setting of acute and chronic overdose of acetaminophen is described in the text. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/1\">",
"      Davidson DG, Eastham WN. Acute liver necrosis following overdose of paracetamol. Br Med J 1966; 2:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/2\">",
"      Seeff LB, Cuccherini BA, Zimmerman HJ, et al. Acetaminophen hepatotoxicity in alcoholics. A therapeutic misadventure. Ann Intern Med 1986; 104:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/3\">",
"      Zimmerman HJ, Maddrey WC. Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure. Hepatology 1995; 22:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/4\">",
"      Maddrey WC. Hepatic effects of acetaminophen. Enhanced toxicity in alcoholics. J Clin Gastroenterol 1987; 9:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/5\">",
"      Whitcomb DC, Block GD. Association of acetaminophen hepatotoxicity with fasting and ethanol use. JAMA 1994; 272:1845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/6\">",
"      Schi&oslash;dt FV, Rochling FA, Casey DL, Lee WM. Acetaminophen toxicity in an urban county hospital. N Engl J Med 1997; 337:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/7\">",
"      Benson GD. Hepatotoxicity following the therapeutic use of antipyretic analgesics. Am J Med 1983; 75:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/8\">",
"      Watson WA, Litovitz TL, Klein-Schwartz W, et al. 2003 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2004; 22:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/9\">",
"      Lee WM. Acetaminophen and the U.S. Acute Liver Failure Study Group: lowering the risks of hepatic failure. Hepatology 2004; 40:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/10\">",
"      Lee WM. Drug-induced hepatotoxicity. N Engl J Med 1995; 333:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/11\">",
"      Ostapowicz G, Fontana RJ, Schi&oslash;dt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002; 137:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/12\">",
"      Lee WM. Acute liver failure in the United States. Semin Liver Dis 2003; 23:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/13\">",
"      Wolf MS, King J, Jacobson K, et al. Risk of unintentional overdose with non-prescription acetaminophen products. J Gen Intern Med 2012; 27:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/14\">",
"      Chun LJ, Tong MJ, Busuttil RW, Hiatt JR. Acetaminophen hepatotoxicity and acute liver failure. J Clin Gastroenterol 2009; 43:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/15\">",
"      Larson AM, Polson J, Fontana RJ, et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 2005; 42:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/16\">",
"      Myers RP, Li B, Fong A, et al. Hospitalizations for acetaminophen overdose: a Canadian population-based study from 1995 to 2004. BMC Public Health 2007; 7:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/17\">",
"      Lewis RK, Paloucek FP. Assessment and treatment of acetaminophen overdose. Clin Pharm 1991; 10:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/18\">",
"      Prescott LF. Paracetamol overdosage. Pharmacological considerations and clinical management. Drugs 1983; 25:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/19\">",
"      Makin AJ, Wendon J, Williams R. A 7-year experience of severe acetaminophen-induced hepatotoxicity (1987-1993). Gastroenterology 1995; 109:1907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/20\">",
"      Forrest JA, Clements JA, Prescott LF. Clinical pharmacokinetics of paracetamol. Clin Pharmacokinet 1982; 7:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/21\">",
"      Bizovi KE, Aks SE, Paloucek F, et al. Late increase in acetaminophen concentration after overdose of Tylenol Extended Relief. Ann Emerg Med 1996; 28:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/22\">",
"      Cetaruk EW, Dart RC, Hurlbut KM, et al. Tylenol Extended Relief overdose. Ann Emerg Med 1997; 30:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/23\">",
"      Tighe TV, Walter FG. Delayed toxic acetaminophen level after initial four hour nontoxic level. J Toxicol Clin Toxicol 1994; 32:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/24\">",
"      Douglas DR, Sholar JB, Smilkstein MJ. A pharmacokinetic comparison of acetaminophen products (Tylenol Extended Relief vs regular Tylenol). Acad Emerg Med 1996; 3:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/25\">",
"      Schi&oslash;dt FV, Ott P, Christensen E, Bondesen S. The value of plasma acetaminophen half-life in antidote-treated acetaminophen overdosage. Clin Pharmacol Ther 2002; 71:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/26\">",
"      Mitchell JR, Jollow DJ, Potter WZ, et al. Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione. J Pharmacol Exp Ther 1973; 187:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/27\">",
"      Manyike PT, Kharasch ED, Kalhorn TF, Slattery JT. Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation. Clin Pharmacol Ther 2000; 67:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/28\">",
"      Corcoran GB, Mitchell JR, Vaishnav YN, Horning EC. Evidence that acetaminophen and N-hydroxyacetaminophen form a common arylating intermediate, N-acetyl-p-benzoquinoneimine. Mol Pharmacol 1980; 18:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/29\">",
"      Bessems JG, Vermeulen NP. Paracetamol (acetaminophen)-induced toxicity: molecular and biochemical mechanisms, analogues and protective approaches. Crit Rev Toxicol 2001; 31:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/30\">",
"      Thummel KE, Lee CA, Kunze KL, et al. Oxidation of acetaminophen to N-acetyl-p-aminobenzoquinone imine by human CYP3A4. Biochem Pharmacol 1993; 45:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/31\">",
"      Kaplowitz N. Acetaminophen hepatoxicity: what do we know, what don't we know, and what do we do next? Hepatology 2004; 40:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/32\">",
"      Lee SS, Buters JT, Pineau T, et al. Role of CYP2E1 in the hepatotoxicity of acetaminophen. J Biol Chem 1996; 271:12063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/33\">",
"      Linden CH, Rumack BH. Acetaminophen overdose. Emerg Med Clin North Am 1984; 2:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/34\">",
"      Gemborys MW, Mudge GH, Gribble GW. Mechanism of decomposition of N-hydroxyacetaminophen, a postulated toxic metabolite of acetaminophen. J Med Chem 1980; 23:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/35\">",
"      James LP, Mayeux PR, Hinson JA. Acetaminophen-induced hepatotoxicity. Drug Metab Dispos 2003; 31:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/36\">",
"      Roberts DW, Pumford NR, Potter DW, et al. A sensitive immunochemical assay for acetaminophen-protein adducts. J Pharmacol Exp Ther 1987; 241:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/37\">",
"      Pumford NR, Hinson JA, Potter DW, et al. Immunochemical quantitation of 3-(cystein-S-yl)acetaminophen adducts in serum and liver proteins of acetaminophen-treated mice. J Pharmacol Exp Ther 1989; 248:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/38\">",
"      Jollow DJ, Mitchell JR, Potter WZ, et al. Acetaminophen-induced hepatic necrosis. II. Role of covalent binding in vivo. J Pharmacol Exp Ther 1973; 187:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/39\">",
"      Black M. Acetaminophen hepatotoxicity. Gastroenterology 1980; 78:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/40\">",
"      Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003; 349:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/41\">",
"      Knight TR, Fariss MW, Farhood A, Jaeschke H. Role of lipid peroxidation as a mechanism of liver injury after acetaminophen overdose in mice. Toxicol Sci 2003; 76:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/42\">",
"      Michael SL, Pumford NR, Mayeux PR, et al. Pretreatment of mice with macrophage inactivators decreases acetaminophen hepatotoxicity and the formation of reactive oxygen and nitrogen species. Hepatology 1999; 30:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/43\">",
"      Blazka ME, Wilmer JL, Holladay SD, et al. Role of proinflammatory cytokines in acetaminophen hepatotoxicity. Toxicol Appl Pharmacol 1995; 133:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/44\">",
"      Liu ZX, Govindarajan S, Kaplowitz N. Innate immune system plays a critical role in determining the progression and severity of acetaminophen hepatotoxicity. Gastroenterology 2004; 127:1760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/45\">",
"      Liu ZX, Kaplowitz N. Role of innate immunity in acetaminophen-induced hepatotoxicity. Expert Opin Drug Metab Toxicol 2006; 2:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/46\">",
"      Ishida Y, Kondo T, Ohshima T, et al. A pivotal involvement of IFN-gamma in the pathogenesis of acetaminophen-induced acute liver injury. FASEB J 2002; 16:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/47\">",
"      Rumack BH, Peterson RC, Koch GG, Amara IA. Acetaminophen overdose. 662 cases with evaluation of oral acetylcysteine treatment. Arch Intern Med 1981; 141:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/48\">",
"      Thummel KE, Slattery JT, Nelson SD. Mechanism by which ethanol diminishes the hepatotoxicity of acetaminophen. J Pharmacol Exp Ther 1988; 245:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/49\">",
"      Schmidt LE, Dalhoff K, Poulsen HE. Acute versus chronic alcohol consumption in acetaminophen-induced hepatotoxicity. Hepatology 2002; 35:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/50\">",
"      Slattery JT, Nelson SD, Thummel KE. The complex interaction between ethanol and acetaminophen. Clin Pharmacol Ther 1996; 60:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/51\">",
"      Perrot N, Nalpas B, Yang CS, Beaune PH. Modulation of cytochrome P450 isozymes in human liver, by ethanol and drug intake. Eur J Clin Invest 1989; 19:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/52\">",
"      Lucas D, M&eacute;nez C, Girre C, et al. Decrease in cytochrome P4502E1 as assessed by the rate of chlorzoxazone hydroxylation in alcoholics during the withdrawal phase. Alcohol Clin Exp Res 1995; 19:362.",
"     </a>",
"    </li>",
"    <li>",
"     Smilkstein MJ. Acetaminophen. In: Goldfrank's Toxicologic Emergencies, Goldfrank LR, Flomenbaum NE, Lewin NA, et al.  (Eds), Appleton &amp; Lange, Stamford 1998. p.541.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/54\">",
"      Smilkstein, MJ. Chronic ethanol use and acute acetaminophen overdose toxicity. J Toxicol Clin Toxicol 1998; 36:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/55\">",
"      Cheung L, Potts RG, Meyer KC. Acetaminophen treatment nomogram. N Engl J Med 1994; 330:1907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/56\">",
"      Rex DK, Kumar S. Recognizing acetaminophen hepatotoxicity in chronic alcoholics. Postgrad Med 1992; 91:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/57\">",
"      Schi&oslash;dt FV, Lee WM, Bondesen S, et al. Influence of acute and chronic alcohol intake on the clinical course and outcome in acetaminophen overdose. Aliment Pharmacol Ther 2002; 16:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/58\">",
"      Girre C, Hispard E, Palombo S, et al. Increased metabolism of acetaminophen in chronically alcoholic patients. Alcohol Clin Exp Res 1993; 17:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/59\">",
"      Lauterburg BH, Velez ME. Glutathione deficiency in alcoholics: risk factor for paracetamol hepatotoxicity. Gut 1988; 29:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/60\">",
"      Lieber CS. Alcohol, liver, and nutrition. J Am Coll Nutr 1991; 10:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/61\">",
"      Prescott LF. Paracetamol, alcohol and the liver. Br J Clin Pharmacol 2000; 49:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/62\">",
"      Rumack BH. Acetaminophen hepatotoxicity: the first 35 years. J Toxicol Clin Toxicol 2002; 40:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/63\">",
"      Dart RC, Kuffner EK, Rumack BH. Treatment of pain or fever with paracetamol (acetaminophen) in the alcoholic patient: a systematic review. Am J Ther 2000; 7:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/64\">",
"      Benson GD. Acetaminophen in chronic liver disease. Clin Pharmacol Ther 1983; 33:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/65\">",
"      Kuffner EK, Dart RC, Bogdan GM, et al. Effect of maximal daily doses of acetaminophen on the liver of alcoholic patients: a randomized, double-blind, placebo-controlled trial. Arch Intern Med 2001; 161:2247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/66\">",
"      Benson GD, Koff RS, Tolman KG. The therapeutic use of acetaminophen in patients with liver disease. Am J Ther 2005; 12:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/67\">",
"      Farrell GC, Cooksley WG, Powell LW. Drug metabolism in liver disease: activity of hepatic microsomal metabolizing enzymes. Clin Pharmacol Ther 1979; 26:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/68\">",
"      Bray GP, Harrison PM, O'Grady JG, et al. Long-term anticonvulsant therapy worsens outcome in paracetamol-induced fulminant hepatic failure. Hum Exp Toxicol 1992; 11:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/69\">",
"      Nolan CM, Sandblom RE, Thummel KE, et al. Hepatotoxicity associated with acetaminophen usage in patients receiving multiple drug therapy for tuberculosis. Chest 1994; 105:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/70\">",
"      Shriner K, Goetz MB. Severe hepatotoxicity in a patient receiving both acetaminophen and zidovudine. Am J Med 1992; 93:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/71\">",
"      Estes JD, Stolpman D, Olyaei A, et al. High prevalence of potentially hepatotoxic herbal supplement use in patients with fulminant hepatic failure. Arch Surg 2003; 138:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/72\">",
"      Lauterburg BH. Analgesics and glutathione. Am J Ther 2002; 9:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/73\">",
"      Price VF, Jollow DJ. Effect of glucose and gluconeogenic substrates on fasting-induced suppression of acetaminophen glucuronidation in the rat. Biochem Pharmacol 1989; 38:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/74\">",
"      Price VF, Miller MG, Jollow DJ. Mechanisms of fasting-induced potentiation of acetaminophen hepatotoxicity in the rat. Biochem Pharmacol 1987; 36:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/75\">",
"      McLean AE. Nutrition and the intracellular site of toxic injury. World Rev Nutr Diet 1978; 29:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/76\">",
"      Ueshima Y, Tsutsumi M, Takase S, et al. Acetaminophen metabolism in patients with different cytochrome P-4502E1 genotypes. Alcohol Clin Exp Res 1996; 20:25A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/77\">",
"      Critchley JA, Nimmo GR, Gregson CA, et al. Inter-subject and ethnic differences in paracetamol metabolism. Br J Clin Pharmacol 1986; 22:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/78\">",
"      de Morais SM, Uetrecht JP, Wells PG. Decreased glucuronidation and increased bioactivation of acetaminophen in Gilbert's syndrome. Gastroenterology 1992; 102:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/79\">",
"      Nelson SD. Molecular mechanisms of the hepatotoxicity caused by acetaminophen. Semin Liver Dis 1990; 10:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/80\">",
"      Rumore MM, Blaiklock RG. Influence of age-dependent pharmacokinetics and metabolism on acetaminophen hepatotoxicity. J Pharm Sci 1992; 81:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/81\">",
"      Tarloff JB, Khairallah EA, Cohen SD, Goldstein RS. Sex- and age-dependent acetaminophen hepato- and nephrotoxicity in Sprague-Dawley rats: role of tissue accumulation, nonprotein sulfhydryl depletion, and covalent binding. Fundam Appl Toxicol 1996; 30:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/82\">",
"      Rumack BH. Acetaminophen overdose in young children. Treatment and effects of alcohol and other additional ingestants in 417 cases. Am J Dis Child 1984; 138:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/83\">",
"      Lauterburg BH, Vaishnav Y, Stillwell WG, Mitchell JR. The effects of age and glutathione depletion on hepatic glutathione turnover in vivo determined by acetaminophen probe analysis. J Pharmacol Exp Ther 1980; 213:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/84\">",
"      Day A, Abbott GD. Chronic paracetamol poisoning in children: a warning to health professionals. N Z Med J 1994; 107:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/85\">",
"      Dong SX, Ping ZZ, Xiao WZ, et al. Effect of active and passive cigarette smoking on CYP1A2-mediated phenacetin disposition in Chinese subjects. Ther Drug Monit 1998; 20:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/86\">",
"      Seo KW, Park M, Kim JG, et al. Effects of benzothiazole on the xenobiotic metabolizing enzymes and metabolism of acetaminophen. J Appl Toxicol 2000; 20:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/87\">",
"      Schmidt LE, Dalhoff K. The impact of current tobacco use on the outcome of paracetamol poisoning. Aliment Pharmacol Ther 2003; 18:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/88\">",
"      Kaysen GA, Pond SM, Roper MH, et al. Combined hepatic and renal injury in alcoholics during therapeutic use of acetaminophen. Arch Intern Med 1985; 145:2019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/89\">",
"      Polson J, Wians FH Jr, Orsulak P, et al. False positive acetaminophen concentrations in patients with liver injury. Clin Chim Acta 2008; 391:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/90\">",
"      McBride, PV, Rumack, BH. Acetaminophen intoxication. Semin Dial 1992; 5:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/91\">",
"      Flanagan RJ, Mant TG. Coma and metabolic acidosis early in severe acute paracetamol poisoning. Hum Toxicol 1986; 5:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/92\">",
"      Singer AJ, Carracio TR, Mofenson HC. The temporal profile of increased transaminase levels in patients with acetaminophen-induced liver dysfunction. Ann Emerg Med 1995; 26:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/93\">",
"      Caldarola V, Hassett JM, Hall AH, et al. Hemorrhagic pancreatitis associated with acetaminophen overdose. Am J Gastroenterol 1986; 81:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/94\">",
"      Mofenson HC, Caraccio TR, Nawaz H, Steckler G. Acetaminophen induced pancreatitis. J Toxicol Clin Toxicol 1991; 29:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/95\">",
"      Erickson, RA, Runyon, BA. Acetaminophen hepatotoxicity associated with alcoholic pancreatitis. Arch Intern Med 1984; 144:1509,.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/96\">",
"      Davenport A, Finn R. Paracetamol (acetaminophen) poisoning resulting in acute renal failure without hepatic coma. Nephron 1988; 50:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/97\">",
"      Blakely P, McDonald BR. Acute renal failure due to acetaminophen ingestion: a case report and review of the literature. J Am Soc Nephrol 1995; 6:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/98\">",
"      Wilkinson SP, Moodie H, Arroyo VA, Williams R. Frequency of renal impairment in paracetamol overdose compared with other causes of acute liver damage. J Clin Pathol 1977; 30:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/99\">",
"      Bj&ouml;rck S, Svalander CT, Aurell M. Acute renal failure after analgesic drugs including paracetamol (acetaminophen). Nephron 1988; 49:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/100\">",
"      Read RB, Tredger JM, Williams R. Analysis of factors responsible for continuing mortality after paracetamol overdose. Hum Toxicol 1986; 5:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/101\">",
"      Ambre J, Alexander M. Liver toxicity after acetaminophen ingestion. Inadequacy of the dose estimate as an index of risk. JAMA 1977; 238:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/102\">",
"      Rumack BH, Matthew H. Acetaminophen poisoning and toxicity. Pediatrics 1975; 55:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/103\">",
"      Douglas, DR, Smilkstein, MJ, Rumack, BH. APAP levels within 4 hours: Are they useful?. Vet Hum Toxicol 1994; 36:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/104\">",
"      Prescott LF, Illingworth RN, Critchley JA, et al. Intravenous N-acetylcystine: the treatment of choice for paracetamol poisoning. Br Med J 1979; 2:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/105\">",
"      Smilkstein MJ, Knapp GL, Kulig KW, Rumack BH. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). N Engl J Med 1988; 319:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/106\">",
"      Vale JA, Proudfoot AT. Paracetamol (acetaminophen) poisoning. Lancet 1995; 346:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/107\">",
"      Bridger S, Henderson K, Glucksman E, et al. Deaths from low dose paracetamol poisoning. BMJ 1998; 316:1724.",
"     </a>",
"    </li>",
"    <li>",
"     Temple AR. \"Dear Doctor\" Tylenol ER letter. Fort Washington, PA. McNeil Consumer Products Company. January 3, 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/109\">",
"      Kumar S, Rex DK. Failure of physicians to recognize acetaminophen hepatotoxicity in chronic alcoholics. Arch Intern Med 1991; 151:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/110\">",
"      Smilkstein MJ, Bronstein AC, Linden C, et al. Acetaminophen overdose: a 48-hour intravenous N-acetylcysteine treatment protocol. Ann Emerg Med 1991; 20:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/43/25274/abstract/111\">",
"      Spooner, JB, Harvey, JG. Paracetamol overdose &mdash; Facts not misconceptions. Pharm J 1993; 251:706.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 340 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.195.65.247-9CA6F9C4F1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_43_25274=[""].join("\n");
var outline_f24_43_25274=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H42644071\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PHARMACOKINETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      BIOCHEMICAL TOXICITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL FACTORS INFLUENCING TOXICITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Acute alcohol ingestion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Chronic alcohol ingestion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Single overdose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Multiple overdoses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Chronic liver disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Nutritional status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Tobacco",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Pattern of use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Stage I (0.5 to 24 hours)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Stage II (24 to 72 hours)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Stage III (72 to 96 hours)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Stage IV (four days to two weeks)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1984922420\">",
"      Acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      General approach and serum acetaminophen concentration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Evaluation after acute overdose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Evaluation after repeated (chronic) overdose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13755278\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H42644071\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/340\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/340|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?36/3/36914\" title=\"diagnostic image 1\">",
"      Acetaminophen toxicity CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/340|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/49/21279\" title=\"figure 1\">",
"      Acetaminophen metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/10/26798\" title=\"figure 2\">",
"      Rumack-Matthews acetaminophen nomogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/56/25472\" title=\"figure 3\">",
"      Acetaminophen poisoning nomogram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/340|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/9/30876\" title=\"table 1\">",
"      Acetaminophen preparations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32937?source=related_link\">",
"      Acetaminophen (paracetamol) poisoning in adults: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/18/34090?source=related_link\">",
"      Approach to the patient with abnormal liver biochemical and function tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/42/21162?source=related_link\">",
"      Clinical manifestations and diagnosis of alcoholic fatty liver disease and alcoholic cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26695?source=related_link\">",
"      Enhanced elimination of poisons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16297?source=related_link\">",
"      Gastrointestinal decontamination of poisoned adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=related_link\">",
"      General approach to drug poisoning in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/51/13114?source=related_link\">",
"      Management of acetaminophen (paracetamol) poisoning in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7591?source=related_link\">",
"      Overview of hepatitis A virus infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/5/30807?source=related_link\">",
"      Pathogenesis of alcoholic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/49/33554?source=related_link\">",
"      Patient information: Acetaminophen poisoning (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5446?source=related_link\">",
"      Patterns of plasma aspartate and alanine aminotransferase levels with and without liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42279?source=related_link\">",
"      Serologic diagnosis of hepatitis B virus infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_43_25275="Caloric balance PN preterm";
var content_f24_43_25275=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64194&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64194&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Caloric balance PN preterm",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Concentration, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        g/kg/day",
"       </td>",
"       <td class=\"subtitle1\">",
"        kcal/kg/day",
"       </td>",
"       <td class=\"subtitle1\">",
"        kcals, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Infusion rate at 135 mL/kg/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Glucose",
"       </td>",
"       <td>",
"        12.5",
"       </td>",
"       <td>",
"        16.9",
"       </td>",
"       <td>",
"        57.5",
"       </td>",
"       <td>",
"        57",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Amino acids",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"       <td>",
"        3.4",
"       </td>",
"       <td>",
"        13.6",
"       </td>",
"       <td>",
"        13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Infusion rate at 15 mL/kg/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lipid",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        3.0",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        30",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Suggested distribution of energy sources in parenteral nutrition solutions for premature infants based upon an assumed total fluid intake of 150 mL/kg per day and total calorie intake is 102 kcal/kg per day.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_43_25275=[""].join("\n");
var outline_f24_43_25275=null;
var title_f24_43_25276="Treatment of Chagas disease";
var content_f24_43_25276=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F65745&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F65745&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment of Chagas disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Treatment of Chagas disease by phase of disease, form of disease, and demographic group",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Should always be offered",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acute",
"        <em>",
"         T. cruzi",
"        </em>",
"        infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Early congenital",
"        <em>",
"         T. cruzi",
"        </em>",
"        infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Children &le;12 years old with chronic",
"        <em>",
"         T. cruzi",
"        </em>",
"        infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Children 13-18 years old with chronic",
"        <em>",
"         T. cruzi",
"        </em>",
"        infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Reactivated",
"        <em>",
"         T. cruzi",
"        </em>",
"        infection in patient with HIV/AIDS or other immunosuppression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Should generally be offered",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Reproductive-age women",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Adults 19-50 years old with indeterminate form, or mild to moderate cardiomyopathy (Kuschnir grades 0, I or II)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Optional",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Adults &gt;50 years old without advanced cardiomyopathy (Kuschnir grades 0, I or II)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chagas gastrointestinal disease patients without advanced cardiomyopathy*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Should generally not be offered",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Advanced chagasic cardiomyopathy with congestive heart failure (Kuschnir grade III)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Megaesophagus with significant impairment of swallowing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Should never be offered",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        During pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Severe renal or hepatic insufficiency",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * There are no data to suggest that treatment affects progression of gastrointestinal disease. Decisions should be based on the potential to decrease risk of development or progression of heart disease.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bern C, Montgomery SP, Herwaldt BL, et al. Evaluation and treatment of chagas disease in the United States: a systematic review. JAMA 2007; 298:2171. Copyright &copy; 2007 American Medical Association. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_43_25276=[""].join("\n");
var outline_f24_43_25276=null;
var title_f24_43_25277="Heart rate control of atrial fib in COPD";
var content_f24_43_25277=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F83353&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F83353&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Intravenous pharmacologic agents for acute heart rate control in patients with atrial fibrillation and chronic obstructive pulmonary disease*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Loading dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Onset",
"       </td>",
"       <td class=\"subtitle1\">",
"        Maintenance dose (for initial 24 to 72 hours)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Major side effects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        There is evidence and/or general agreement that the following drugs are effective for acute heart rate control in patients with AF who do NOT have an accessory pathway or heart failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Verapamil &yen;",
"       </td>",
"       <td>",
"        0.075 to 0.15 mg/kg (max 10 mg per dose) IV over 2 minutes, may repeat dose in 15 to 30 minutes if inadequate response to initial dose",
"       </td>",
"       <td>",
"        3 to 5 minutes",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Hypotension, heart block, heart failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diltiazem &yen;",
"       </td>",
"       <td>",
"        0.25 mg/kg IV over 2 minutes (max 25 mg initial dose), may repeat with higher dose (0.35 mg/kg IV) in 15 to 30&nbsp;minutes if inadequate response to initial dose",
"       </td>",
"       <td>",
"        2 to 7 minutes",
"       </td>",
"       <td>",
"        5 to 15 mg/hour IV infusion titrated according to ventricular heart rate",
"       </td>",
"       <td>",
"        Hypotension, heart block, heart failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Metoprolol &yen;",
"        <sup>",
"         &bull;&Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        2.5 to 5 mg IV over 2 minutes; up to 3 doses (maximum 15 mg total) administered 5 to 10 minutes apart may be given",
"       </td>",
"       <td>",
"        5 minutes",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Hypotension, heart block, bradycardia, heart failure, bronchoconstriction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        For acute heart rate control in patients with AF and an accessory pathway",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Amiodarone &yen;",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        150 mg IV over 30 minutes, followed by 1 mg/minute IV infusion for 6 hours, followed by 0.5 mg/minute IV infusion for 18 hours",
"       </td>",
"       <td>",
"        1 to 30 minutes",
"       </td>",
"       <td>",
"        0.5 mg/minute IV infusion for up to additional 48 hours",
"       </td>",
"       <td>",
"        Hypotension, sinus bradycardia, heart block, QT prolongation, ventricular arrhythmias, pulmonary toxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        For acute heart rate control in patients with AF and heart failure but not an accessory pathway",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Digoxin &yen;",
"        <sup>",
"         &sect;������",
"        </sup>",
"       </td>",
"       <td>",
"        0.25 mg IV every 2 hours, up to a total dose of 1.5 mg",
"       </td>",
"       <td>",
"        15 to 30 minutes, peak effect in 1 to 5 hours",
"       </td>",
"       <td>",
"        0.125 to 0.25 mg orally once a day",
"       </td>",
"       <td>",
"        Digitalis toxicity, heart block, bradycardia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Amiodarone &yen;",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        150 mg IV over 30 minutes, followed by 1 mg/minute IV infusion for 6 hours, followed by 0.5 mg/minute IV infusion for 18 hours",
"       </td>",
"       <td>",
"        1 to 30 minutes",
"       </td>",
"       <td>",
"        0.5 mg/minute IV infusion for up to additional 48 hours",
"       </td>",
"       <td>",
"        Hypotension, sinus bradycardia, heart block, QT prolongation, ventricular arrhythmias, pulmonary toxicity",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * For patients with hemodynamic instability due to atrial fibrillation, direct current cardioversion is the treatment of choice. For all patients with COPD and atrial fibrillation with a rapid ventricular response, correction of hypoxemia, acidosis, and other metabolic disturbances is recommended. Theophylline can increase the ventricular response, so dosing should be regulated to keep the serum level in the range of 8 to 12 mg/mL; discontinuation of the medication should be considered.",
"     <br>",
"      <font class=\"bullet\">",
"       &yen; Electrocardiographic (ECG or telemetry) and blood pressure monitoring should be continuously performed during initial loading dose and frequently (eg, every&nbsp;4 hours) during maintenance intravenous&nbsp;dosing.",
"       <br>",
"        &bull;",
"       </br>",
"      </font>",
"      Representative of the type of selective beta-1 blockers that could be used but similar drugs could be given in appropriate doses.",
"      <br>",
"       &Delta; Nondihydropyridine calcium channel antagonists (eg, verapamil, diltiazem) are preferred over metoprolol for heart rate control of atrial fibrillation in patients with COPD due to concerns about exacerbating bronchoconstriction.",
"       <br>",
"        <font class=\"lozenge\">",
"         &loz;",
"        </font>",
"        Amiodarone can be useful when other measures are unsuccessful or contraindicated. For patients with an accessory pathway, intravenous amiodarone can be given if the rhythm cannot be converted or ablated and rate control is needed.",
"        <br>",
"         &sect; There is evidence and/or general agreement that digoxin is effective in patients with heart failure but not an accessory pathway.",
"         <br>",
"          &Dagger; Dosing shown is for normal renal function and normal body weight. Reduced doses are needed for renal insufficiency or low body weight.&nbsp;Refer to topic on &ldquo;Method of digitalization&rdquo;.",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_43_25277=[""].join("\n");
var outline_f24_43_25277=null;
var title_f24_43_25278="Pharmacology antidepressants";
var content_f24_43_25278=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F53818&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F53818&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Usual daily dose of antidepressants for adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Starting dose per day (mg)*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Usual total dose per day for treament of depression (mg)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Generic available in US",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Selective serotonin reuptake inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Citalopram",
"       </td>",
"       <td>",
"        10 to 20",
"       </td>",
"       <td>",
"        20 to 40",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Escitalopram",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        10 to 20",
"       </td>",
"       <td>",
"        yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fluoxetine",
"       </td>",
"       <td>",
"        10 to 20",
"       </td>",
"       <td>",
"        20 to 60",
"       </td>",
"       <td>",
"        yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fluvoxamine",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        50 to 300",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fluvoxamine CR",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        100 to 300",
"       </td>",
"       <td>",
"        no",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Paroxetine",
"       </td>",
"       <td>",
"        10 to 20",
"       </td>",
"       <td>",
"        20 to 60",
"       </td>",
"       <td>",
"        yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Paroxetine CR",
"       </td>",
"       <td>",
"        12.5 to 25",
"       </td>",
"       <td>",
"        25 to 75",
"       </td>",
"       <td>",
"        yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sertraline",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        50 to 200",
"       </td>",
"       <td>",
"        yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Serotonin-norepinephrine reuptake inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Venlafaxine",
"       </td>",
"       <td>",
"        37.5",
"       </td>",
"       <td>",
"        75 to 300 as two or three divided doses",
"       </td>",
"       <td>",
"        yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Venlafaxine XR",
"       </td>",
"       <td>",
"        37.5",
"       </td>",
"       <td>",
"        75 to 300",
"       </td>",
"       <td>",
"        yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Desvenlafaxine",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        50 (no titration)",
"       </td>",
"       <td>",
"        no",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Duloxetine",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        60 to 120",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        no",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Dopamine-norepinephrine reuptake inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bupropion",
"       </td>",
"       <td>",
"        75 to 150 as two divided doses",
"       </td>",
"       <td>",
"        300 to 450 as three divided doses",
"       </td>",
"       <td>",
"        yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bupropion SR 12 hour",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        300 to 400 as two divided doses",
"       </td>",
"       <td>",
"        yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bupropion XL 24 hour",
"       </td>",
"       <td>",
"        150",
"       </td>",
"       <td>",
"        300 to 450",
"       </td>",
"       <td>",
"        no",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bupropion hydrobromide 24 hour",
"       </td>",
"       <td>",
"        174",
"       </td>",
"       <td>",
"        348 to 522",
"       </td>",
"       <td>",
"        no",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Serotonin modulators",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nefazodone",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        300 to 600",
"       </td>",
"       <td>",
"        yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Trazodone",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        75 to 500",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Trazodone ER",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        75 to 375",
"       </td>",
"       <td>",
"        no",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Noradrenergic and specific serotonergic antidepressant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mirtazapine",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        15 to 45",
"       </td>",
"       <td>",
"        yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Tricyclics and tetracyclics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Amitriptyline",
"       </td>",
"       <td>",
"        25 to 50",
"       </td>",
"       <td>",
"        100 to 300",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Amoxapine",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        100 to 400",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Clomipramine",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        100 to 250",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Desipramine",
"       </td>",
"       <td>",
"        25 to 50",
"       </td>",
"       <td>",
"        100 to 300",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Doxepin",
"       </td>",
"       <td>",
"        25 to 50",
"       </td>",
"       <td>",
"        100 to 300",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Imipramine",
"       </td>",
"       <td>",
"        25 to 50",
"       </td>",
"       <td>",
"        100 to 300",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Maprotiline",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        100 to 225",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nortriptyline",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        50 to 150",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Protriptyline",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        15 to 60 as three or four divided doses",
"       </td>",
"       <td>",
"        yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Trimipramine",
"       </td>",
"       <td>",
"        25 to 50",
"       </td>",
"       <td>",
"        100 to 200",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Monamine oxidase inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Isocarboxazid",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        10 to 40 as two to four divided doses",
"       </td>",
"       <td>",
"        no",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Phenelzine",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        15 to 90 as three or four divided doses",
"       </td>",
"       <td>",
"        no",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Selegiline transdermal",
"       </td>",
"       <td>",
"        6 mg patch",
"       </td>",
"       <td>",
"        6 to 12 patch",
"       </td>",
"       <td>",
"        no",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tranylcypromine",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        30 to 60 as three or four divided doses",
"       </td>",
"       <td>",
"        yes",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Total daily dose shown is for oral administration, except as noted.",
"    <div class=\"footnotes\">",
"     * A lower starting dose may be necessary in the elderly or in patients with significant comorbidities. Lower initial doses may also reduce the incidence of adverse events in some patients.",
"     <br>",
"      <font class=\"bullet\">",
"       &bull;",
"      </font>",
"      Maximum recommended dose of citalopram is 20 mg for patients &gt;60 years of age, with significant hepatic insufficiency, or taking interacting medications that can increase citalopram levels. Refer to topics on unipolar depression&nbsp;for more information.&nbsp;Specific interactions of citalopram with other medications may be determined using the drug interactions tool (Lexi-Interact Online) included in UpToDate. This tool can be accessed from the UpToDate online search page or through the individual drug information topics in the section on Drug interactions.",
"      <br>",
"       &Delta; As two or three divided doses or may be given as a single dose at bedtime, except if dose is at upper end of range.",
"       <br>",
"        &loz;&nbsp;Caution: can cause liver failure. Not available in Europe, Canada, and several other countries.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_43_25278=[""].join("\n");
var outline_f24_43_25278=null;
var title_f24_43_25279="TTS balloon";
var content_f24_43_25279=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F66533&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F66533&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Through-the-scope (TTS) esophageal balloon dilator",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 305px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left panel; Primary inflation width of the TTS balloon. Right panel: Three incremental increases in balloon size.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Boston Scientific/Microvasive.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_43_25279=[""].join("\n");
var outline_f24_43_25279=null;
